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1.1 BACKGROUND AND AIM OF THE STUDY 
Homeostasis is an essential aspect of the mammalian immune system. Under normal 
conditions, many bacteria live in coexistence with the human body. Especially the skin, the 
gastrointestinal tract or the external urogenital organs contain bacteria, not causing any harm 
to the organism. But, pathogenic as well as commensal microorganisms or their constituents, 
such as lipopolysaccharide (LPS), evoke an immune response after passing the barrier 
between the external and internal environment of the body. Sepsis, severe sepsis and septic 
shock describe a complex clinical syndrome, which results from an exaggerated host 
response to microbial infection. Sepsis develops when the initial, appropriate host response 
becomes amplified and then deregulated. When an organ system begins to fail because of 
sepsis, the sepsis is considered severe, once occurred, leading to approximately 50% 
mortality. Therefore, sepsis is the leading cause of mortality in intensive care units. An 
understanding of the mechanisms involved in sepsis and septic shock is essential to design 
new therapeutic strategies, to prevent sepsis, and thus improve the outcome after microbial 
infection.  
The atrial natriuretic peptide (ANP) is a peptide hormone mainly secreted by the cardiac 
atria, in response to atrial stretch, reflecting increased intravascular volume. After the 
discovery of the atrial natriuretic peptide, the hormone was thought to mainly possess 
cardiovascular effects, in summary, regulation of blood pressure and plasma volume 
expansion. Interestingly, atrial natriuretic peptide receptors were found to be expressed in 
diverse tissues besides the cardiovascular and renal system, such as thymus, spleen, lymph 
nodes as well as isolated macrophages. The ANP and ANP-receptor expression is regulated 
by various immunomodulatory agents. Therefore, a great effort has already been done to 
study the coherence of ANP and the immune system.  
For a long time, increased plasma levels of atrial natriuretic peptide have only thought to be 
elevated in patients with congestive heart failure. Recently, ANP has attracted interest as a 
new marker in the field of sepsis.  Plasma levels of ANP and its precursor protein pro-ANP 
have been demonstrated to be highly increased in septic patients. For this reason, 
endogenous ANP might not only be considered a marker but also a regulatory mediator in 
inflammation and sepsis. With regard to severe inflammatory processes during endotoxemia, 
TNF-α has been demonstrated to be one of the leading pro-inflammatory cytokines. 
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During the last years, in our laboratory a lot of work has been done to investigate the 
interrelation of ANP and the immune system. Following LPS stimulation, we demonstrated 
that ANP is able to prevent TNF-α expression in macrophages in vitro. Furthermore, the 
atrial natriuretic peptide has quite recently been shown to protect from LPS-induced septic 
shock in vivo. The influence of ANP leads to a strong decrease in serum TNF-α levels and 
finally promotes survival of infected mice. Therefore, aim of the present work was to 
elucidate the ANP mediated protective mechanisms involved in LPS-induced septic shock. 
First, we aimed to answer the following question.  
• How do different organs contribute to decreased serum TNF-α levels in LPS-induced    
  sepsis in mice? 
The liver is the central organ in whole body metabolism and plays a pivotal role in natural 
immune response of the host to infection. Especially resident liver macrophages are 
activated by several bacterial stimuli and produce various cytokines, such as TNF-α. 
Therefore, the liver seems to be one of the most interesting organs in LPS-induced septic 
shock, pointing to several questions. 
• In which way does ANP preconditioning influence the inflammatory processes in the liver 
  during LPS-induced septic-shock? 
• Which cell type within the liver is mainly involved in inflammatory processes? 
The liver constantly contains a rich blood supply, consistent with its important metabolic and 
immunomodulatory functions. In previous studies we demonstrated that ANP prevents LPS-
induced TNF-α expression in whole human blood. Hence, we wanted to investigate the 
influence of ANP on LPS-induced TNF-α expression in different blood leukocytes. 
• Does primarily LPS-induced TNF-α release from macrophages evoke proximate organ 
  answers? 
• How does ANP preconditioning interfere within this LPS-induced TNF-α expression in  
  leukocytes? 
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1.2 NATRIURETIC PEPTIDES 
The basic natriuretic peptide (NP) family comprises atrial, brain and C-type natriuretic 
peptide. These peptides mainly mediate natriuretic, diuretic, vasorelaxant and mitogenic 
responses.  Atrial natriuretic peptide (ANP) is the first hormone, which has been described 
for the natriuretic peptide family ([44] de Bold, 1981). In 1988 urodilatin was isolated from the 
human urine. This peptide being synthesized in kidney tubules belongs to the A-type 
natriuretic peptides, representing a differentially processed molecular form ([51] Forssmann, 
2001; [160] Schulz-Knappe, 1988). Besides the A-type natriuretic peptides, two more 
members, B-type or brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP) 
have been identified. BNP, which shares a highly homologous structure with ANP has first 
been isolated from the porcine brain, and therefore, named “brain natriuretic peptide” ([168] 
Sudoh, 1988). Following BNP discovery, a second natriuretic peptide has been isolated from 
the porcine brain, and in accordance to ANP and BNP it has been called CNP, C-type 
natriuretic peptide ([169] Sudoh, 1990). Although, as seen in Figure 1:1, ANP, BNP and CNP 
share a highly homologous structure, they differ in their site of synthesis and show 
preferences for specific cell surface receptors. Therefore, natriuretic peptides most likely 
influence different biological functions ([148] Pandey, 2005). Besides these three well known 
peptide hormones two more groups of natriuretic like peptides have been discovered, to 
date. The first group, Dendroaspis natriuretic peptides (DNPs) has been identified in 1992.  
DNPs, which are structurally homologous to other natriuretic peptides, have been isolated 
from the venom of the green mamba, Dendroaspis angusticeps ([162] Schweitz, 1992). First 
studies indicate, that DNP or DNP related peptides might also be present in the human body 
([153] Richards, 2002). The second group, TNPs, taipan venom natriuretic peptides including 
TNP-a, TNP-b and TNP-c, has been discovered in the venom of the inland taipan, 
Oxyuranus microlepidotus ([53] Fry, 2005).  
ANP BNP DNPCNP
 
Figure 1:1 ANP, BNP, CNP and DNP constitute the main members of the natriuretic peptide family.  
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1.2.1 NATRIURETIC PEPTIDE RECEPTORS 
Natriuretic peptides mediate their effects by interacting with their corresponding high-affinity 
receptors on the surface of target cells. The existence of different natriuretic peptides proves 
the complexity of their role in regulating diverse biological functions. This complexity further 
seems to be increased by the availability of different natriuretic peptide specific receptor 
proteins. In mammalian tissue, three different natriuretic peptide receptors have been 
identified to date (Figure 1:2) ([148] Pandey, 2005): 
 • natriuretic peptide receptor A =  NPR-A =  A-type receptor 
 • natriuretic peptide receptor B =  NPR-B =  B-type receptor 
 • natriuretic peptide receptor C =  NPR-C =  C-type receptor 
=  clearance receptor 
The hormonal activities of ANP and BNP are mainly mediated by the A-type natriuretic 
receptor. This receptor generally exhibits ligand selectivity for ANP and BNP, but hardly for 
CNP, and mediates most of the known actions of the natriuretic peptides. The closely related 
B-type receptor binds all natriuretic peptides, with main preference for CNP. Both receptors, 
NPR-A and NPR-B are coupled to guanylate-cyclase (GCase) and generate cyclic-
guanosine-monophosphate (cGMP) in response to hormone binding. An increase in 
intracellular cGMP mediates hormonal activities through cGMP regulated effector molecules. 
NPR-A as well as NPR-B belong to a large family of receptors, that share a common overall 
molecular configuration ([113] Levin, 1998; [134] Misono, 2002; [173] Tremblay, 2002). The 
C-type natriuretic receptor lacks the GCase domain. Interestingly, NPR-C binds all natriuretic 
peptides with equal affinity. After binding of natriuretic peptides, NPR-C triggers removal of 
excess of these peptides from the circulation. It has been reported, that binding of CNP to 
NPR-C inhibits adenylate-cyclase (ACase) activity and activates phosphatidylinositol 
turnover. But to date,  NPR-C has not directly been linked to any of the known hormonal 
effects of the natriuretic peptides ([136] Misono, 2005).  
Natriuretic peptide receptors are distributed in different mammalian tissues, for example the 
cardiovascular system, the kidney, thymus and the spleen ([105] Kurihara, 1986; [139] 
Napier, 1984; [182] Vollmar, 2005). We are primarily interested in signaling pathways 
involved in LPS-induced inflammation in liver. Therefore, it is of main interest that  
NP-receptors are generally expressed in rodent and in human liver cells ([183] Vollmar, 
1997; [194] Yip, 1985). 
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Figure 1:2 Structure and binding specificities for natriuretic peptide receptors. After extracellular binding 
at the NPR-A or NPR-B, cGMP is elevated in the cytosol. The C-type natriuretic peptide 
receptor is able to clear natriuretic peptides and exerts other biological effects. NPR-A 
preferably binds ANP and BNP, whereas NPR-B binds CNP.  The C-type natriuretic peptide 
receptor does not show any preferences and equally binds ANP, BNP and CNP. 
1.2.2 ATRIAL NATRIURETIC PEPTIDE STRUCTURE AND FUNCTION 
In 1981, the atrial natriuretic peptide has first been described by de Bold et al. ([44] de Bold, 
1981). As shown in Figure 1:3, the atrial natriuretic peptide is a circular peptide hormone 
based on 28 amino acids, containing a disulfide bond between two cysteine residues 
(cysteine 7 to cysteine 23). The resulting 17 amino acid ring structure is highly conserved 
among natriuretic peptides and essential for its biological activity ([135] Misono, 1984). The 
biosynthesis of ANP is typical for different peptide hormones. Pre-pro-ANP, a 151 amino acid 
pre-pro-hormone is generated, which is cleaved at the N-terminus, resulting in a 126 amino 
acid storage form, called pro-ANP. This peptide contains its biological active form in its 
carboxyl-terminus region. 
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Following stimulation, pro-ANP is cleaved into an amino-terminal fragment and its biological 
active peptide, ANP ([80] Inagami, 1989; [148] Pandey, 2005). Finally, the atrial natriuretic 
peptide is released into circulation from granules of the heart atrium via exocytosis ([140] 
Newman, 1991). 
 
Figure 1:3 Structure and amino-acid sequence of the human atrial natriuretic peptide. The peptide 
consists of a highly conserved 17 amino acid ring-structure. This element is quite homologous 
among all natriuretic peptides and seems to be essential for its biological activity.  
ANP elicits a variety of responses, which are basically directed toward the reduction of blood 
pressure and volume homeostasis. Therefore, the primary stimulus for ANP secretion is 
exerted by increased atrial-wall tension, due to elevation of venous blood pressure ([80] 
Inagami, 1989; [113] Levin, 1998; [148] Pandey, 2005; [170] Suzuki, 2001).  After secretion 
into the plasma, atrial natriuretic peptide promotes diuresis and natriuresis, following 
reduction of extracellular fluid volume. This effect is provoked by direct interacting of ANP 
with tubular actions in the kidney ([113] Levin, 1998). ANP further mediates vasodilatation 
and inhibition of the renin-angiotensin-aldosterone system ([170] Suzuki, 2001). Interestingly, 
besides atrial distension a number of additional stimuli have been identified to induce ANP 
secretion from the heart, such as angiotensin-II and different cytokines. Surprisingly, several 
immunomodulatory agents are able to induce ANP expression, pointing to important 
functions of atrial natriuretic peptide in the immune system ([182] Vollmar, 2005).  
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1.2.3 ANP AND THE IMMUNE SYSTEM 
First evidence for the link between the cardiovascular hormone, ANP, and the immune 
system has been found by detecting atrial natriuretic peptide besides the cardiovascular 
system in lymphoid organs ([184] Vollmar, 1990). Upon these investigations, it was 
discovered that ANP is not only distributed, but also produced by cells of the immune 
system, such as macrophages ([185] Vollmar, 1994). The corresponding atrial natriuretic 
peptide receptors are located in cells belonging to the innate, as well as the adaptive immune 
system ([182] Vollmar, 2005).  In 1993, cGMP coupled effects of ANP on phagocytotic 
activity  have primarily been described in macrophages ([94] Kiemer, 2002a; [127] Mattana, 
1993).  Additionally, ANP treatment of resident liver macrophages, also denoted as Kupffer 
cells, has been shown to significantly increase phagocytotic activity via the A-type natriuretic 
peptide receptor ([94] Kiemer, 2002a; [127] Mattana, 1993).  However, ANP does not only 
influence cellular defense mechanisms of macrophages but also interferes with signaling 
pathways induced by various pro-inflammatory stimuli. As subsequently described, to date, 
ANP is known to exhibit several anti-inflammatory properties. These properties were 
investigated in vitro, such as in macrophages and endothelial cells, as well as in vivo, for 
instance in mice ([91] Keller, 2005a; [96] Kiemer, 2002b; [182] Vollmar, 2005). 
1.2.3.1 INFLUENCE OF ANP ON LPS-INDUCED INFLAMMATORY PROCESSES 
Following LPS-stimulation, macrophages produce large amounts of nitric-oxide (NO) via 
inducible NO-synthase (iNOS), which is an important mediator of host response. On the 
transcriptional level, ANP has been shown to markedly inhibit the LPS-mediated activation of 
the transcription factor NF-κB, which is crucial for the transcriptional activation of iNOS. 
Consequently ANP prevented the formation of NO. Moreover, it has been investigated that 
ANP mediated iNOS regulation does not just depend on transcriptional but also on post-
transcriptional processes in murine macrophages ([97] Kiemer, 1997; [98] Kiemer, 1998). 
Furthermore, in vivo, ANP has been demonstrated to affect the COX2 system by significantly 
attenuating the thromboxane-B2 and prostaglandine-E2 (PGE2) production in LPS treated 
mice. Continuatively, in murine macrophages, ANP was shown to influence the PGE2 
production predominantly via the C-type natriuretic peptide receptor and cAMP, involving 
reduced COX2-protein and COX2-mRNA level ([96] Kiemer, 2002b). 
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Following activation, ANP inhibits TNF-α expression in LPS-stimulated bone marrow-derived 
macrophages as well as in LPS-stimulated human whole blood. These findings are 
consistent with diminished TNF-α mRNA levels ([95] Kiemer, 2000; [99] Kiemer, 2001). 
Interestingly, in LPS treated isolated Kupffer cells, ANP reduces TNF-α expression. This 
reduction of TNF-α secretion in ANP-preconditioned, LPS-stimulated Kupffer cells is 
accompanied by an increased amount of cell associated TNF-α. Even though, LPS-induced 
TNF-α mRNA expression was not affected. Therefore, atrial natriuretic peptide supposedly 
influences translational as well as post-translational processing of TNF-α ([94] Kiemer, 
2002a). 
1.2.3.2 INFLUENCE OF ANP ON TNF-α-INDUCED INFLAMMATORY PROCESSES 
The ability of ANP to inhibit induction of inflammatory mediators, such as iNOS, COX2 and 
TNF-α, represents important aspects supporting its anti-inflammatory properties. To elevate 
complexity, atrial natriuretic peptide does not only decrease expression of the pro-
inflammatory cytokine TNF-α, but also interferes with TNF-α mediated signaling pathways in 
endothelial cells. 
Recently, it has been demonstrated that pretreatment of endothelial cells with atrial 
natriuretic peptide strongly reduces TNF-α induced expression of mRNA and cell surface 
protein levels, such as E-selectin and ICAM-1. These effects in turn are associated with 
inhibition of TNF-α-induced activation of the transcription factor NF-κB ([101] Kiemer, 
2002d). TNF-α is also known to induce vascular permeability. In our laboratory, ANP has 
been demonstrated to abrogate TNF-α induced changes in vascular permeability associated 
with  stress-fiber formation and actin polymerization, involving cGMP and p38 MAPK 
dependent signaling pathways ([100] Kiemer, 2002c). 
1.2.3.3 CYTOPROTECTIVE EFFECTS OF ANP 
Besides its protective potential in different inflammatory mechanisms, ANP also contributes 
to various cytoprotective processes. Thus, atrial natriuretic peptide has frequently been 
shown to protect against ischemia/reperfusion injury in different organs, such as in liver. The 
production of cytoprotective proteins, like heat shock proteins, by ANP might account for 
these beneficial actions ([17] Bilzer, 1994; [57] Gerwig, 2003; [182] Vollmar, 2005). 
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1.3 SEPSIS, SEVERE SEPSIS AND SEPTIC SHOCK 
A very essential aspect of the mammalian immune system is to maintain homeostasis. 
Usually, many bacteria live in coexistence with the human body. Especially the skin, the 
gastrointestinal tract and part of the urogenital organs contain bacteria, not causing any harm 
to the organism. The presence of these microorganisms is not a threat to the body, since 
these organs play a pivotal role in connecting the sterile “internal environment” with the 
“external environment”. However, pathogenic as well as commensal microorganisms or their 
constituents, evoke a strong immune response after passing the barrier between the external 
and internal environment of the body ([174] van Amersfoort, 2003). Sepsis develops, when 
the initial infection becomes amplified and dysregulated. Interestingly, sepsis does not define 
a certain state but rather describes a complex clinical syndrome, resulting from an 
overwhelming host response (Table 1:1). Therefore, sepsis is an infection-induced syndrome 
defined as the presence of two or more of the following features of systemic inflammation:  
    - hyperthermia/fever or hypothermia  
   - leucokytosis or leucopenia  
    - tachycardia (> 90 beats/minute) or tachypnea (> 20 breath/minute).  
When an organ system begins to fail, the sepsis is considered to be severe ([189] Wheeler, 
1999). Hepatic failure is a common start of septic decompensation, thus followed by multiple 
organ failure, often resulting in septic shock ([32] Ceydeli, 2003). The overall mortality due to 
sepsis is approximately 30%, rising up to 40% in the elderly and becomes elevated up to 
50% or greater in patients suffering from severe sepsis and septic shock ([4] Alberti, 2002; 
[35] Cohen, 2002).  If four or five organs fail, the mortality will be even greater than 90%. The 
knowledge about the molecular mechanisms of sepsis rapidly increased over the past 
decades. Unfortunately, the therapeutic approaches used to treat sepsis have not become 
very successful, to date ([141] Nguyen, 2003). 
SIRS  
systemic inflammatory 
response syndrome 
sepsis severe sepsis septic shock 
severe injury in the 
absence of infection 
systemic inflammatory 
response to an infection 
organ failure because of 
sepsis 
severe sepsis combined 
with massive hypotension 
 mortality  
approximately 30% 
mortality  
approximately 50% 
mortality  
50% up to 90% 
Table 1:1 The different faces of sepsis.  
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1.3.1 THE INFLAMMATORY CASCADE  
Multiple organ failure is the ultimate cause of death in patients with sepsis. Usually, patients 
will first develop a single organ dysfunction, which commonly results in failure of further 
organ systems. Primarily, the septic machinery is highly influenced by extensive cross-talk 
between different cascades of inflammatory mediators. Upon activation, these cascades 
affect various pro- and anti-coagulant pathways, finally leading to the clinical septic 
syndrome (Figure 1:4) ([83] Johnson, 1996; [84] Johnson, 1998). 
Sepsis occurs due to a microbial infection mainly with bacteria or bacterial components, such 
as lipopolysaccharide (LPS), a cell wall component of gram-negative bacteria. The initial 
host-microbial interaction involves a strong activation of the innate immune system, leading 
to coordination of the host-defense response. Once activated, mononuclear cells, like 
macrophages/monocytes, immediately release classic pro-inflammatory cytokines, such as 
TNF-α and IL-1 ([172] Tom van der Poll, 1999). Investigations on the kinetic of cytokine 
release have shown that the first pro-inflammatory cytokine appearing in human circulation is 
supposed to be TNF-α. Amounts of TNF-α in plasma are soon detectable and peak 90 
minutes after microbial-infection ([47] Dinarello, 1997; [175] Van Der, 1997). Following the 
initial response, a secondary level of the inflammatory cascade is activated, involving various 
cytokines, lipid mediators, reactive oxygen species and cell adhesion molecules. The latter 
results in leukocyte-endothelial cell interaction initiating inflammatory cell migration into 
tissues ([188] Weigand, 2004). Together, these mediators are playing a key role by forming a 
complex network of secondary responses  to microbial-infection ([35] Cohen, 2002).  
Cytokines are also important in inducing a pro-coagulant effect in sepsis. Following 
microbial-infection, mononuclear and endothelial cells are activated, resulting in expression 
of tissue factor (TF) by these cells. Thereon, tissue factor activates numerous proteolytic 
cascades, leading to conversion of pro-thrombin to thrombin, which generates fibrin from 
fibrinogen.  At the same time anti-coagulant cascades are impaired because of high plasma 
levels of plasminogen-activator inhibitor (PAI), thus preventing the generation of plasmin 
from plasminogen. Under normal conditions, fibrin is broken down by plasmin, ensuing 
homeostasis in coagulation. Together, these effects not only enhance production but also 
reduce removal of fibrin. This consequently leads to disproportion of pro-coagulant cascades 
and anti-coagulant mechanisms ([35] Cohen, 2002; [172] Tom van der Poll, 1999).  
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Additionally, down-regulation of three anti-coagulant proteins; anti-thrombin (AT), activated 
protein C (APC) and tissue factor pathway inhibitor (TFPI), contribute to the pro-coagulant 
condition during sepsis. Interestingly, these proteins not only influence coagulation but also 
exert important anti-inflammatory properties. These properties include inhibition of activation 
of the transcription factor NF-κB, thus decreasing TNF-α release by monocytes ([144] 
Okajima, 2001; [195] Yuksel, 2002). All these findings indicate a strong interplay between 
mediators of the inflammatory and coagulant cascade. 
endothelium neutrophils monocytes
complement
chemotaxis
microvascular occlusion vascular instability
procoagulant effect
tissue factor &
plasminogen activator
inhibitor
oxygen radicals lipid mediators
coagulopathy fever vasodilatation capillary leak
sepsis and multiple organ failure
bacteria and bacterial components
cytokines
 
Figure 1:4 The pathogenetic network in septic shock (adapted from ([35] Cohen, 2002). LPS and various 
microbial components activate multiple inflammatory cascades that contribute to the clinical 
syndrome of sepsis. Finally, the combination of impaired peripheral vascular tone and micro-
vascular occlusion leads to severe tissue hypo-perfusion, resulting in organ failure. 
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1.3.2 SIGNALING MECHANISMS INVOLVED IN SEPSIS 
As described previously, bacteria and bacterial components, fungi, viruses and parasites are 
recognized by the innate immune system. All of them might elicit strong pro-inflammatory 
responses, which can result in a sepsis syndrome (1.3.1). Bacterial components include 
lipopolysaccharide (LPS) from gram-negative bacteria and lipoteichoic acid (LTA) derived 
from gram-positive bacteria. LPS and LTA are main building parameters of the outer 
bacterial cell walls. Even though, all microorganisms and their products are able to induce 
severe inflammation, gram-negative bacteria-derived LPS is supposed to be the most 
common cause for sepsis to date ([5] Alexander, 2001; [125] Marshall, 2005). 
1.3.2.1 LPS SIGNALING 
The microbial motifs, such as LPS, that are recognized by the immune system are termed 
pathogen-associated molecular patterns (PAMPs). These motifs are not characterized by 
specific binding sites but rather comprise various typical patterns. These patterns are 
identified by toll-like receptors that are capable of binding various microbial motifs ([12] 
Beutler, 2003). 
Toll-like receptors 
The family of toll-like receptors has been discovered by identification of the drosophila 
protein Toll. This protein is expressed by various insects and is supposed to be essential for 
developmental functions ([6] Anderson, 1985). Ten years ago, studies revealed that TLRs 
are not only involved in embryogenesis but also participate in the innate immune response 
against fungal infections of Drosophila ([112] Lemaitre, 1996). In 1998, the TLR-4 was 
primarily identified as the lipopolysaccharide-recognition receptor, 
required for mice to respond to infection caused by gram-negative 
bacteria ([150] Poltorak, 1998). Up to now, 13 mammalian toll-like 
receptors have been identified, whereof ten of them have been 
found in humans ([13] Beutler, 2004; [146] Palsson-McDermott, 
2004) . Today, in 2006, it seems to be taken for granted that Toll-
like receptors are central recognition proteins during microbial 
infections. 
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Figure 1:5 TLR-4 schematic structure.
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Toll-like receptors (Figure 1:5) are transmembrane proteins, all of which exhibit a common 
extracellular leucine-rich region (known as leucine rich repeats, LRR) and a highly conserved 
intracellular cytoplasmic domain. This domain is structurally homologous to cytoplasmic 
structures located in various interleukin (IL) receptors, and therefore, termed toll/IL-1 receptor 
homology domain (TIR) ([165] Slack, 2000). On the basis of this homology toll-like receptors 
belong to the TLR/IL-1R-superfamily ([48] Dunne, 2003). 
Toll-like receptor-4 mediated LPS signaling 
As seen in Figure 1:6, probably the first protein involved in LPS recognition is LPS-binding 
protein (LBP) ([161] Schumann, 1990). LBP circulates in the bloodstream where it forms a 
high affinity complex with LPS, appearing either as fragments, free molecules or still bound 
to the outer membrane of intact bacteria. Thereby, the apparent role of LBP is to guide LPS 
in activating the TLR complex, by binding LPS and forming a complex with a third molecule 
CD14 ([192] Wright, 1990). CD14 is found, as a membrane bound and soluble form. The 
latter occurs in plasma, helping to convoy LPS signaling in cells lacking membrane bound 
CD14. Membrane bound CD14 is attached to the outer cell membrane. Interestingly it does 
not exhibit a transmembrane domain, handicapping CD14 to transfer LPS signaling from the 
cell surface into the cytosol. The toll-like receptor complex exists of TLR-4 and MD-2, an 
extracellular adaptor protein that seems to be essential within the LPS signaling cascade 
([159] Schromm, 2001). Therefore, MD-2 is supposed to be involved in ligand recognition by 
the receptor and TLR-4 sensitization for LPS binding ([180] Visintin, 2001). After activation of 
the TLR-complex, LPS-TLR-4 signaling is initiated by the formation of a TLR-4 homodimer. 
Following MD-2-TLR-4 dimerization, several combinations of signaling molecules become 
associated with the receptor complex. Primarily, intracellular myeloid differentiation factor-88 
(MyD88) is recruited to the TLR complex by its TIR domain ([131] Medzhitov, 1998). 
However, the TLR-4 mediated response to LPS can be divided into two main signaling 
pathways: - the early phase MyD88-dependent response ([12] Beutler, 2003)  
    - consecutively, the delayed MyD88-independent response ([89] Kawai, 1999; 
[90] Kawai, 2001). Since we are mainly interested in early events during LPS-induced sepsis, 
we will now focus on the MyD88-dependent pathway. 
The early response – the MyD88-dependent pathway 
MyD88 is recruited to the TLR-complex by its own TIR domain, which is able to interact with 
the TIR domain of TLR-4.  Hence, this allows the further attraction and activation of 
downstream IL-1 receptor associated kinases (IRAK) ([81] Janssens, 2003).  
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IRAK4 is primarily recruited to the complex, subsequently leading to association and 
phosphorylation of IRAK1. Now, formation of the complex results in TNF-receptor associated 
factor-6 (TRAF6) activation that is immediately recruited to the receptor complex ([26] 
Bradley, 2001). Phosphorylated IRAK1 and TRAF6 dissociate from the receptor complex, 
which may induce phosphorylation of mitogen-activated protein kinases (MAPK) (further 
described under 1.3.2.4) and activation of the transcription factor NF-κB (further described 
under 1.3.2.3). This finally allows the expression of different target genes, such as TNF-α ([3] 
Akira, 2004; [12] Beutler, 2003; [146] Palsson-McDermott, 2004). Interestingly, LPS 
stimulation has also been shown to result in phosphorylation of MyD88, and the formation of 
a PI3K-MyD88 complex, following activation of the protein kinase Akt. However, binding of 
NF-κB to DNA is not affected by inhibition of Akt-kinase activation during LPS-induced 
inflammation (see chapter 1.3.2.4) ([116] Li, 2003; [143] Ojaniemi, 2003). 
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Figure 1:6 The early phase, MyD88 dependent TLR-4 mediated LPS signaling pathways.
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1.3.2.2 TNF-α SIGNALING 
Tumour necrosis factor-α (TNF-α) is one of the most commonly investigated pro-
inflammatory cytokines produced by various cell types of the immune system, like 
monocytes/ macrophages. TNF-α is responsible for a wide range of signaling events in acute 
inflammation and autoimmune disorders. This leads either to inflammatory processes, 
necrosis, cell survival or apoptosis ([2] Aggarwal, 2003; [11] Baud, 2001). Thus, the 
importance of TNF-α in the pathogenesis of inflammation and sepsis has often been 
described ([118] Lin, 2005). Trials that involved the administration of low doses of microbial 
endotoxins (LPS) to healthy human volunteers resulted in elevated TNF-α plasma levels, 
peaking 90 minutes after LPS administration ([133] Michie, 1988; [176] van Deventer, 1990). 
TNF-α processing 
Tumor necrosis factor-α exists in two biologically active forms. It is initially expressed as a 
precursor 233-amino-acid transmembrane protein (memTNF-α). Following activation, the 
soluble 157-amino-acid, TNF-α (solTNF-α) is proteolytically liberated from the cell membrane 
by cleavage of its precursor protein. Thereby, memTNF-α undergoes shedding by 
metalloproteases, particularly TNF-α-cleaving enzyme (TACE) ([55] Gearing, 1994). TACE is 
a membrane bound enzyme that belongs to a disintegrin and metalloproteases (ADAMs) 
family ([19] Black, 1997). Interestingly, it has been shown that treatment with a TACE 
inhibitor prevents mortality in LPS/D-galactosamine induced sepsis in mice ([137] Mohler, 
1994). Therefore, the consequent release of solTNF-α by TACE on cells of the immune 
system is  an important factor in the pathophysiology of sepsis ([155] Robertshaw, 2005). 
Signal transduction by tumor necrosis factor receptor-1 
To date, there are two known TNF receptors, TNF receptor-1 (TNFR-1) and TNF receptor-2 
(TNFR-2). TNF-α mainly mediates its effects by binding to its TNFR-1 ([178] Vandenabeele, 
1995). Interestingly, none of the mammalian TNF receptors itself comprises any enzymatic 
activity. As seen in Figure 1:7, binding of a TNF-α trimer to its receptor induces receptor 
trimerization and several signaling proteins are recruited to the cytoplasmic domain of the 
receptor ([10] Banner, 1993). Following stimulation, TNFR-1 associated death domain 
protein (TRADD) is the first protein recruited to the receptor ([77] Hsu, 1995). At this point, 
TRADD subsequently recruits further effector proteins into the TNF-TNFR-TRADD-complex. 
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Three molecules have been shown to directly interact with the TRADD protein:   
    - FAS-associated death domain protein (FADD) ([33] Chinnaiyan, 1995)   
    - TNF receptor associated factor 2 (TRAF2)    
    - receptor interacting protein (RIP) ([75] Hsu, 1996a).   
By now, these proteins are able to activate various signaling cascades, finally resulting in 
different TNF-mediated effects ([76] Hsu, 1996b). The protein FADD is very important for 
TNF-α induced apoptosis. This occurs by further activating a cascade of caspases, including 
initiator-caspase 8. TRAF2 and the serine-threonine kinase RIP are critical in pathways 
leading to cell survival and inflammatory processes. Thus, these proteins are mainly involved 
in activation of the transcription factors NF-κB and AP1. Additionally, TRAF2 and RIP are 
required for mitogen-activated protein kinase (MAPK) activation ([46] Devin, 2003; [71] 
Hehlgans, 2005; [120] Liu, 2005). 
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Figure 1:7 Signal transductions pathways activated by tumor necrosis factor receptor-1 stimulation.
The choice between life and death is often one of the main events in TNF-α-mediated 
regulation of the immune system. Interestingly, the pathology that is linked to TNF-α is also 
often associated with an inappropriate NF-κB activation. 
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1.3.2.3 NF-κB  
As seen before, many of the LPS and TNF-α-caused effects are mediated through the 
activation of the transcription regulating factor, nuclear factor-κB (NF-κB). To date, over 200 
genes have been shown to be regulated by NF-κB, and their products are involved in a huge 
variety of diseases ([2] Aggarwal, 2003). For example, NF-κB is mainly involved in 
modulating the expression of many immune-regulatory mediators, such as TNF-α, that 
participate in acute inflammatory response after microbial infection ([68] Hanada, 2002). 
Interestingly, NF-κB binding activity has already been studied in peripheral blood 
mononuclear cells (PBMC) of septic patients, whereas non-survivors could be distinguished 
from survivors by an increase in NF-κB binding activity. Additionally, in a murine sepsis 
model, intravenous gene transfer with IκBα was able to attenuate LPS-induced NF-κB 
binding activity and increase survival ([1] Abraham, 2003; [23] Bohrer, 1997). In account of 
this, NF-κB and its regulatory signaling pathways have recently become an interesting fact 
for intensive drug discovery ([88] Karin, 2004). 
Of course, NF-κB can not function by itself, therefore a variety of proteins and mechanisms 
are involved in order to regulate transcription factor activity. The NF-κB (Rel) transcription 
factors always act as dimers. So far, five known mammalian NF-κB/Rel proteins, belonging 
to two classes have been identified: “class-1”: - Rel (c-Rel); p65 (RelA) and RelB  
       “class-2”: - p50 and p52.   
 “Class-1” proteins are synthesized as mature products whereas “class-2” proteins are 
synthesized as large precursor proteins, p105 and p100 that require proteolytic processing to 
produce the mature p50 and p52 NF-κB proteins ([59] Ghosh, 1998).  The NF-κB protein 
exists in the cytoplasm in an inactive form, as a result of NF-κB association with its inhibitory 
proteins, IκBs. Among these proteins, the most common forms are IκBα, IκBβ and IκBε. The 
most established theory is that IκB proteins keep NF-κB in the cytoplasm by masking their 
nuclear-localization sequences located on NF-κB subunits ([78] Huxford, 1998). Nowadays, 
several studies have indicated that localization not only depends on IκB binding but also on 
balancing continuous movement between the nuclear and cytoplasmic regions ([18] Birbach, 
2002). Untouched, the canonical pathway involved in NF-κB activation is still believed to be 
based on IκBα degradation (Figure 1:8). A crucial step in this process is the phosphorylation 
of IκBα at two serine residues (serine 32 and serine 36), that is mediated by IκB-kinase (IKK) 
complex ([179] Viatour, 2005). 
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The most common form of this IKK complex consists of several proteins, such as IKKα 
(IKK1), IKKβ (IKK2) and the NF-κB essential modulator (NEMO, IKKγ). Both, IKKα as well as 
IKKβ comprise kinase activity, responsible for IκBα phosphorylation, whereas the regulatory 
protein NEMO contains motifs known to be involved in protein-protein interactions. Answers 
to pro-inflammatory stimuli, as TNF-α or LPS, are largely dependent on IKKβ catalytic 
subunit activation ([85] Karin, 1999). Following phosphorylation IκBα is subsequently 
ubiquitinylated, which targets the protein for degradation by the proteasome ([86] Karin, 
2000). The released NF-κB dimer translocates into the nucleus, binds DNA and activates 
gene transcription ([24] Bonizzi, 2004; [58] Ghosh, 2002; [87] Karin, 2002; [114] Li, 2002a). 
In addition to IκBα modification, the NF-κB subunits, mainly p65, are phosphorylated. This 
phosphorylation is mediated by protein kinases, such as Akt (further described under 
1.3.2.4), which are supposed to play a very important role in regulating NF-κB transcriptional 
activity. To date, it is still not clarified weather phosphorylation of subunits modulates NF-κB, 
to either activate or repress gene expression. ([179] Viatour, 2005; [197] Zhong, 1998; [196] 
Zhong, 2002). 
p
p
nucleus
p50 p65
IκBα
NF-κB
cytosol
extra-
cellular
p
p50 p65
IκBα u
u
uu
p50 p65
activation via LPS, TNF-α
IKKα IKKβ
NEMO
Akt
gene expression
cytokines
chemokines
enzymes
adhesion molecules
p
proteasome
 
Figure 1:8 The NF-κB activating system. After activation of the IKK complex, IκB is subsequently 
phosphorylated, following immediate ubiquitinylation and degradation by the proteasome. The 
“free” NF-κB dimer migrates into the nucleus, binds to DNA and activates gene expression. 
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1.3.2.4 PROTEIN KINASES 
After LPS binding, toll-like receptors activate various intracellular signaling molecules in 
addition to NF-κB discussed previously. These signaling molecules include different protein 
kinases, such as mitogen activated protein kinases (MAPK), particularly p38 MAPK, 
phosphatidylinositol 3 kinases (PI3K) and protein kinase Akt. 
p38 MAPK 
The pro-inflammatory cytokine TNF-α has an important function in cell signaling pathways 
involved in sepsis. Several of the molecular mechanisms that regulate LPS-induced TNF-α-
mediated responses have been discussed in detail (for review see chapter 1.3.2.2). 
Additionally, mitogen activated protein kinases, are one group of enzymes that respond to 
various extracellular stimuli, such as LPS. Three subgroups of MAPK have been identified to 
date:  - extracellular-signal-regulated kinases (Erks)  
   - c-Jun amino-terminal kinases (JNKs)  
   - p38 MAPK.  
Following stimulation, MAPK are activated by a MAPK activation-cascade. Thereby, the 
MAPKK-kinase activates the targeted MAPK-kinase by phosphorylation. Proximately, the 
MAPK-kinase (MAPKK), for instance the MKK3 or MKK6, activates the corresponding 
MAPK, as p38 MAPK. Interestingly, the p38 MAPK was originally identified in LPS-stimulated 
murine macrophages, first described as a 38-kDa polypeptide that underwent tyrosine 
phosphorylation in response to LPS treatment. Since, this peptide has been identified in 
yeast, these findings primarily linked the LPS-induced mammalian signaling pathway to the 
pathway in yeast correlated with stress-response ([67] Han, 1994). Nowadays, p38 MAPK 
has frequently been shown to be critically involved in LPS-induced TNF-α gene expression 
([111] Lee, 1994; [171] Sweet, 1996). In human macrophages, inhibition of LPS-induced p38 
MAPK activation decreases not only TNF-α protein and TNF-α mRNA expression but also 
NF-κB activation. Therefore, p38 MAPK is likely to regulate TNF-α gene-transcription via a 
NF-κB dependent pathway ([29] Campbell, 2004; [31] Carter, 1999b; [30] Carter, 1999a; [82] 
Jiang, 2002). In addition, post-transcriptional regulatory mechanisms leading to reduced 
TNF-α expression have recently been noticed. Thus, LPS-stimulation of murine 
macrophages results in TNF-α mRNA stabilization, which was reversed by specific p38 
MAPK inhibition ([27] Brook, 2000; [123] Mahtani, 2001). As MAPK signaling is more and 
more elucidated it is becoming evident that these pathways might be important targets for 
novel anti-inflammatory drugs in the near future ([64] Guha, 2001; [107] Kyriakis, 2001). 
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PI3 kinase - Akt pathway 
PI3 kinases are activated during toll-like receptor signaling, supposedly, as a result of direct 
interaction of PI3K with the intracellular domain of the TLR-4 or MyD88 ([103] Koyasu, 2003; 
[143] Ojaniemi, 2003). Activation of the PI3K occurs via phosphorylation, which permits 
docking of PI3K to the plasma membrane. PI3 kinases are an enzyme family that catalyzes 
the phosphorylation of cell membrane components, so-called phosphoinositides. These lipid 
substrates are important second messengers for intracellular signaling pathways. Hence, 
activated PI3 kinases provoke membrane changes by phosphorylation of phosphoinositides, 
allowing downstream protein kinase-B, also denoted as Akt to translocate to the cell 
membrane (Figure 1:9). After membrane recruitment, Akt is activated by dual 
phosphorylation at serine 473 and threonine 308 residues, further influencing NF-κB 
dependent gene expression. To date, the PI3K-Akt pathway is supposed to play an important 
role in regulating different cellular functions involving defense and immune responses ([3] 
Akira, 2004; [103] Koyasu, 2003). 
Studies on the role of the PI3K-Akt pathway in NF-κB dependent cell signaling are 
controversial. Therefore, this pathway is discussed to act positively, as well as negatively, on 
NF-κB dependent inflammatory parameters. Recently, it has been demonstrated that 
inhibition of PI3K strongly enhances LPS-induced inflammation and significantly reduces 
survival of septic mice ([157] Schabbauer, 2004). Moreover, activation of the PI3K-Akt 
pathway has been shown to decrease LPS-
induced TNF-α expression via reduced NF-κB 
activation in human peripheral blood monocytes 
([65] Guha, 2002).  Together, these findings 
indicate that the PI3K-Akt pathway strongly 
regulates LPS-induced gene expression in vitro 
as well as in vivo. However, the downstream 
mechanisms targeting the expression of pro-
inflammatory cytokines, such as TNF-α, are still 
incompletely understood  ([117] Liew, 2005; 
[179] Viatour, 2005). 
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Figure 1:9 PI3 kinase – Akt pathway.
Besides classical inflammatory pathways, protein kinases, such as p38 MAPK and Akt, have 
been demonstrated to influence transcription factor activity and cytokine gene expression, 
making these proteins very interesting for investigations during inflammation and sepsis. 
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1.4 SEPSIS & INFLAMMATION  -  IN VIVO AND EX VIVO 
In chapter 1.3, I discussed the major difficulties to clearly stage human sepsis. In order to 
study the sepsis pathology, various models of sepsis and septic shock have been 
established to date ([28] Buras, 2005). These experiments are often used as a preliminary 
testing ground for protective agents and can be divided into three main categories:  
    - exogenous administration of a toxin ( LPS-models)  
    - exogenous administration of a viable pathogen (bacterial-models)  
    - alteration of the animals endogenous protective barrier  
Human volunteer studies have shown that injection of low doses of endotoxins can induce 
patho-physiological alterations similar to those reported in septic patient ([50] Fink, 1990). 
For this reason, amongst all versions, endotoxicosis models (LPS-models) are widely used. 
Indeed, animal models neither completely copy human sepsis, nor involve identical critical-
care delivered to septic patients. However, it will be possible to improve upon animal models 
by better staging and in conclusion appropriately treating patients with sepsis ([28] Buras, 
2005; [49] Esmon, 2004). 
In our laboratory, an animal experiment demonstrated that ANP pretreatment highly 
contributes to survival of LPS-induced sepsis in mice ([91] Keller, 2005a). In order to further 
analyze ANP interference with different signaling pathways involved in LPS-induced 
inflammation and sepsis, we decided to focus on two different systems, the liver and blood 
leukocytes. Both of them are mainly involved in primary immune host responses to microbial 
infection. 
1.4.1 THE LIVER 
The liver is the largest solid organ in the human body, constituting 
of up to 5% of the body weight in adults. Via the portal vein, the 
liver is constantly provided with nutrients from the gastrointestinal 
tract. The function of the liver is the uptake of these nutrients, their 
storage, metabolic conversion and their distribution to the 
circulation. However, the liver does not only participate in 
metabolic pathways but also comprises various clearance functions. Being the first organ 
confronted with microbial products derived from the gastrointestinal tract, the liver is highly 
involved in host-defense mechanisms. 
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Therefore, this organ is an important source of cytokines, participates in bacterial clearance 
and is often injured as a result of inflammation and sepsis ([9] Ashare, 2005; [174] van 
Amersfoort, 2003; [177] van Oosten, 2001). 
The liver is made up of several cell populations, whereas the most abundant cell type by 
mass and by number is the hepatocyte. Besides hepatocytes, the liver is composed of:  
    - resident immune cells (e.g. Kupffer cells)   
    - mesenchymal cells with fibrogenic potential (e.g. hepatic stellate cells)   
    - specialized cells (e.g. endothelial cells).  
Since we are mainly interested in immune responses during sepsis, we will now briefly focus 
on two types of cells within the liver that have frequently been described to strongly interact 
during inflammatory disorders ([138] Monshouwer, 2003; [151] Ramadori Guiliano, 2005). 
Hepatocytes 
Hepatocytes (a) comprise 60% of the total number and 
80% of the whole liver volume. These cells are arranged 
in plates or cords, that branch and merge in a 
continuous labyrinth. By forming such a complex cell 
network, sinusoidal cavities (c) are evolving between 
these hepatocyte formations. In detail, hepatocytes do 
not hold direct contact to sinusoidal cavities but rather 
adjoin to sinusoidal endothelial cells (b). These 
endothelial cells line the whole sinusoidal space and 
therefore constitute the primary barrier between the permanent blood-flow in the sinusoids 
and hepatocytes. Hence, the different sides of hepatocytes are either attached to adjacent 
hepatocytes, border bile canaliculi or are exposed to the sinusoidal space.  Being the 
“workhorses” of the liver, hepatocytes contain the whole machinery that is necessary to carry 
out the different vital functions, such as uptake, storage and metabolism of nutritions ([124] 
Malarkey, 2005; [138] Monshouwer, 2003). Therefore, the degree of hepatic failure, as a 
result of sepsis, is often related to the extent of hepatocyte damage. LPS has frequently 
been shown to directly lead to hepatocyte dysfunction. Interestingly, hepatocyte functions are 
not only influenced by LPS but also by TNF-α from LPS-activated Kupffer cells ([186] Wang, 
1995; [187] Wang, 1998). 
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Kupffer cells 
Kupffer cells account for approximately another 15% of total liver cells but constitute the 
largest amount of resident tissue macrophages in the human body, making up to 90% of 
these cells. They are attached to the luminal face of liver sinusoids anchored to endothelial 
cells.  Interestingly, Kupffer cells are mainly strategically situated in the periportal area, 
where the blood enters the liver. Hence, these cells constitute the very first population of 
macrophages to be faced with bacteria and microbial debris derived from the blood stream 
([39] Cotran, 1999). Therefore, clearance of circulating microbial products is one of the most 
important roles played by Kupffer cells. It is well known that endotoxins are a potent 
stimulator of Kupffer cells, which then induce the production of various mediators. Once 
activated, Kupffer cells release cytokines, nitric oxide (NO), proteases and reactive oxygen 
species (ROS) ([7] Arii, 2000; [45] Decker, 1998; [167] Su, 2002).  In respect of cytokines, 
Kupffer cells are thought to be the principal source of TNF-α and conclusively represent the 
main cellular mediators of LPS-induced effects in the liver ([16] Bilzer, 2005; [92] Keller, 
2005b; [110] Lee, 2004). 
1.4.2 BLOOD LEUKOCYTES - MONOCYTES AND NEUTROPHILS 
As mentioned above, the survival of humans often depends on their ability to recognize 
invading pathogenic organisms and to respond rapidly and adequately. These defense 
mechanisms are innate to the organism. Moreover, the innate 
immune system includes cellular as well as non-cellular constituents. 
Neutrophilic granulocytes (neutrophils) and monocytes are the main 
components in these cellular elements.  They both constitute a large 
quantity amongst white blood cells, also denoted as blood 
leukocytes. The LPS-stimulated release of proinflammatory 
cytokines, such as TNF-α, by human leukocytes is an important component of the 
inflammatory process ([43] Das, 2000; [64] Guha, 2001; [147] Pan, 2000). Through their 
unique combination of cellular functions, leukocytes represent an important first line defense 
to invading microorganisms or their products. In our laboratory, it has recently been shown 
that ANP preconditioning reduces TNF-α expression in LPS-activated whole human blood, 
ex vivo ([95] Kiemer, 2000). Interestingly, these investigations reflect similar effects seen in 
plasma derived from ANP-preconditioned LPS-treated mice ([91] Keller, 2005a). Thus, we 
were interested how ANP-preconditioning influences LPS-induced TNF-α expression in 
whole blood samples of mice as well as of human origin. 
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2.1 MURINE MODEL OF LPS-INDUCED SEPTIC SHOCK 
Animal experiments were kindly performed by Melanie Keller (Ludwig-Maximilians-University 
of Munich, Department of Pharmacy) and Ulla Gebert (Biochemical Pharmacology, 
University of Konstanz). 
2.1.1 ANIMALS 
For the model of LPS-induced septic shock pathogen-free male BALB/c mice were supplied 
by the house animal breeding facility of the University of Konstanz. The animals had free 
access to water and chow (Sniff), but were kept of chow with free access to water 12 hours 
prior to in vivo experiments. Animals were housed in a temperature and humidity controlled 
room under a constant light/dark cycle. All studies were performed with the permission of the 
government authorities in accordance with the German Legislation on Laboratory Animal 
Experiments, and followed the directives of the University of Konstanz Ethical Committee. 
2.1.2 MATERIAL AND SOLUTIONS 
The following materials were used during animal experiments, in the model of LPS-induced 
septic shock. 
Table 2:1 Material used for animal experiments.
product company 
ANP1 - Atrial Natriuretic Peptide (rat) Calbiochem Novabiochem 
LPS1 - Lipopolysaccharide  
  Salmonella abortus equi S. 
Bioclot 
Nembutal® - Pentobarbital Sanofi-Ceva 
TNF-α 
ELISA 
- enzyme linked immuno sorbent assay Amersham Pharmacia Biotech 
 
1 ANP and LPS were diluted in a total volume of 300µl of an endotoxin free sterile   
  0.9% sodium chloride (NaCl) solution containing 0.1% human serum albumin (HSA). 
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2.1.3 EXPERIMENTAL SETTING 
Septic shock has been induced by injection of a sublethal dose of LPS. Whereas, 15 minutes 
previous to LPS challenge, mice were treated with either ANP or sterile pyrogen-free 0.9% 
sodium chloride (NaCl) solution. Following LPS injection, organ and blood samples were 
obtained after lethal intravenous anesthesia with Nembutal plus administration of Heparin at 
the indicated time points. Organ samples were snap-frozen in liquid nitrogen and blood was 
withdrawn by cardiac puncture. 
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Figure 2:1 Treatment of animals. 
 
Table 2:2 Treatment groups of animals. 
group treatment animals 
control NaCl  0.9 % (i.v.) 5 
ANP ANP 
NaCl  
5
0.9
µg/kg b.wt. 
% 
(i.v.) 
(i.v.) 
5 
LPS NaCl 
LPS  
0.9
3
%  
mg/kg b.wt. 
(i.v.) 
(i.v.) 
5 
ANP/LPS ANP 
LPS  
5
3
µg/kg b.wt. 
mg/kg b.wt 
(i.v.) 
(i.v.) 
5 
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2.2 LIVER CELL CULTURE 
In order to investigate signaling pathways in specific cell types, we used the model of primary 
isolated rat hepatocytes. 
2.2.1 ANIMALS 
For isolation of hepatocytes male Sprague-Dawley rats (220-280g) were purchased from 
Charles River WIGA GmbH. Animals had free access to water and chow (Sniff) up to the 
time of experiments. Rats were housed in a temperature and humidity controlled room under 
a constant light/dark cycle. The study was registered with the local animal welfare committee. 
2.2.2 MATERIAL AND SOLUTIONS  
The following materials and solutions were used for isolation and culture of primary rodent 
hepatocytes. Before use, solutions have always been freshly prepared. 
Table 2:3 Material used for isolation of primary hepatocytes. 
product  company 
ANP  - Atrial Natriuretic Peptide (rat) Bachem 
BD Falcon™  - 100µm Cell Strainer BD Biosciences 
Collagen R  Serva 
Collagenase H Roche Diagnostics GmbH 
FCS - Foetal Calf Serum Gibco Invitrogen Corporation 
Insulin   - Insuman® Rapid 40 I.E./ml Aventis 
LPS,   - Lipopolysaccharide 
  Salmonella abortus equi S. 
Bioclot 
Medium  - Leibovitz’s L-15 special Pan Biotech GmbH 
Percoll™   Amersham Biosciences 
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Solution A pH 7.35 Solution B pH 7.35
115 mM  NaCl 115 mM  NaCl 
25 mM  NaHCO3 25 mM  NaHCO3
5.9 mM KCl 5.9 mM  KCl 
1.18 mM  MgCl2  1.18 mM  MgCl2
1.18 mM  MgCl2  1.23 mM  NaH2PO4
1.23 mM  NaH2PO4  1.2 mM  Na2SO4
1.2 mM  Na2SO4  2.5 mM  CaCl2
  H2O  20 mM  Hepes 
    0.05 %  Collagenase H 
      H2O 
 
Hanks’ balanced salt solution pH 7.35 Leibovitz’s L-15 medium  
0.95 mM CaCl2  8.3 mM Glucose 
5.3 mM KCl  2 mM Glutamine 
0.44 mM KH2PO4  2.5 µg/ml Dexamethasone 
0.49 mM MgCl2  100 U/ml Penicillin G 
0.41 mM MgSO4  100 µg/ml Streptomycin 
136.75 mM NaCl  50 µg/ml Gentamycin 
0.34 mM Na2HPO4  50 µg/ml BSA 
20 mM Hepes  5 % FCS 
  H2O  in Leibovitz’s medium 
    add if necessary: 
    125 U/l Insulin 
 
Percoll™ gradient   Trypan blue solution  
136 mM NaCl  0.08 g Trypan blue 
10.2 mM Na2HPO4  0.03 g NaCl 
2.68 mM KCl  20 ml H2O 
1.46 mM KH2PO4    
0.5 mM MgCl2    
50 % Percoll™ solution     
  H2O     
 
Collagen     
5 ml Collagen R     
45 ml  H2O     
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2.2.3 ISOLATION OF PRIMARY HEPATOCYTES 
Rat livers for isolation of hepatocytes were kindly provided by Stephanie Kulhanek-Heinze 
and Florian Hoffmann ((Ludwig-Maximilians-University of Munich, Department of Pharmacy). 
In brief, hepatocytes were isolated using a modified two step collagenase digestion method. 
Male Sprague-Dawley rats (200-300g) were anaesthetized by injection of Narcoren. 
Additionally, 250 I.U. Heparin were administered to avoid blood clotting.  The liver was 
perfused with solution A. Afterwards, the organ was flushed with solution A and subsequently 
perfused in a circulating manner with solution B containing Collagenase H for several 
minutes. Both solutions have been oxygenated for 15 minutes with Carbogen (5% CO2 and 
95% O2) at 37°C. Hereon, the liver was carefully excised and placed into a Petri dish, which 
contained solution B. 
The following procedure was performed in a laminar flow work bench. The hepatic cells were 
isolated by tearing apart the capsule of the liver and scraping out the cells with a teaspoon. 
The cell suspension was filtered with a Falcon cell strainer following sedimentation of the 
cells for 10 minutes.  After discarding the supernatant, the hepatocytes were separated from 
the obtained cell suspension by Percoll density gradient centrifugation (2000rpm, 10 minutes, 
4°C). After centrifugation, the three layers of the supernatant were removed and the 
remaining pellet was suspended in Leibovitz’s L-15 Medium. Cell number and viability was 
determined by staining the hepatocytes with trypan blue (500µl trypan blue solution, 450µl 
solution B, 50µl cell suspension) in a Neubauer counting chamber. Cells were used for 
experiments when vitality exceeded 80%. Subsequently 106 cells/well were seeded into 
collagen R coated 6 well plates containing 1ml of Leibovitz’s L-15 medium. After waiting for 
four hours, cells were washed twice with Hanks’ balanced salt solution and new medium 
lacking insulin was added. Hepatocytes were used for experiments after 24h and 48h of 
culture. 
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2.2.4 EXPERIMENTAL SETTING 
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Figure 2:2 Treatment of primary isolated hepatocytes. 
 
Table 2:4 Treatment groups of primary isolated hepatocytes. 
groups treatment 
control NaCl 0.9 % 
ANP ANP 
NaCl 
25
0.9
nM 
% 
LPS NaCl 
LPS 
0.9
10
% 
µg/ml 
ANP/LPS ANP 
LPS 
25
10
nM 
µg/ml 
TNF-α NaCl 
TNF-α 
0,9
10
% 
ng/ml 
ANP/TNF-α ANP 
TNF-α 
25
10
nM 
ng/ml 
LPS+TNF-α NaCl 
LPS 
TNF-α 
0,9
10
10
% 
µg/ml 
ng/ml 
ANP/LPS+TNF-α ANP 
LPS 
TNF-α 
25
10
10
nM 
µg/ml 
ng/ml 
2 Material and methods   - 32 -    
2.3 BLOOD 
Whole blood experiments were performed to analyze changes on TNF-α protein and  
mRNA expression in murine and human blood leukocytes. 
2.3.1 MATERIAL AND SOLUTIONS 
Table 2:5 Material used for whole blood experiments. 
product  company 
ANP - Atrial Natriuretic Peptide (rat) Bachem 
LPS - Lipopolysaccharide 
  Salmonella abortus equi S. 
Bioclot 
Medium - Iscove’s MEM PromoCell 
Heparin - Heparin-Natrium Braun 25000 I.E/5 ml Braun 
BD Cytofix/Cytoperm™ Plus Kit with GolgiPlug™ BD Biosciences 
 
2.3.2 SAMPLE GENERATION 
Blood sample generation has always been kindly performed by PD. Dr. Zahler   
(Ludwig-Maximilians-University of Munich, Department of Pharmacy). 
2.3.2.1 SAMPLE GENERATION OF HUMAN BLOOD 
Human blood was drawn from healthy male volunteers. Blood was collected by venipuncture 
into a previously heparinized1 sterile blood collection tube. To prevent cooling of the samples, 
subsequently, blood was divided into 200µl portions for FACS analysis alternatively 1ml 
portions for mRNA extraction and kept at 37°C, 5% CO2 until used for experiments. 
1 50IE/ml human blood = 200µl/20ml blood 
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2.3.2.2 SAMPLE GENERATION OF MOUSE BLOOD 
Blood was withdrawn by puncture of the heart. After anesthesia by ether, heparin1 was 
injected intraperitoneally, in order to prevent blood clotting. The mouse thorax has been 
opened very carefully and blood was collected by puncture of the ventricle into a previously 
heparin coated sterile blood collection tube. For leukocyte experiments, we were able to 
withdraw approximately 600µl of whole mouse blood. To prevent cooling of the samples, 
subsequently, blood was diluted 1:1 with medium, divided into 200µl portions and kept at 
37°C, 5% CO2. 
 1 50IE/ml mouse blood = 20µl/mouse 
 
2.3.3 EXPERIMENTAL SETTING 
The stimulus was added in the appropriate concentration for the indicated time points. 
Gained samples were stimulated with LPS and, if indicated, supplementary BD GolgiPlug 
has been applied. Thereby, 15 minutes previous to LPS challenge, ANP or 0.9% NaCl 
solution was added to whole blood samples. Following incubation at 37°C, 5% CO2, vials 
were gently shaken and whole blood samples were used for FACS staining and PCR 
analysis. 
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Figure 2:3  Treatment of whole blood samples. 
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Table 2:6  Treatment groups of whole blood samples.  
group treatment 
control (+ BD GolgiStop) NaCl 
BD GolgiStop 
0.9
1
% 
µl/ml  = 0.01% Brefeldin A 
ANP (+ BD GolgiStop) ANP 
ANP 
NaCl 
BD GolgiStop 
25
1
0.9
1
nM 
µM 
% 
µl/ml  = 0.01% Brefeldin A 
LPS (+ BD GolgiStop) NaCl 
LPS  
LPS 
LPS 
BD GolgiStop 
0.9
100
1
10
1
% 
ng/ml 
µg/ml 
µg/ml 
µl/ml  = 0.01% Brefeldin A 
ANP/LPS (+ BD GolgiStop) ANP 
ANP 
LPS 
LPS 
LPS 
BD GolgiStop 
25
1
100
1
10
1
nM 
µM 
ng/ml 
µg/ml 
µg/ml 
µl/ml  = 0.01% Brefeldin A 
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2.4 WESTERN BLOT ANALYSIS 
Actually, the term “western blot analysis” only characterizes a process of protein transfer 
onto a membrane. Usually, “western blot analysis” is termed to describe the whole process of 
protein separation and protein transfer, following immunological detection of specific 
proteins. 
2.4.1 MATERIAL AND SOLUTIONS 
 
Lysis buffer for liver tissue samples  Laemmli sample buffer 3x 
50 mM NaCl  187.5 mM Tris-HCl 
50 mM Hepes  6 % SDS 
5 mM EDTA  30 % Glycerol 
50 mM NaF  0.015 % Bromphenolblue 
10 mM Na4P2O7    H2O 
1 mM Na3VO4   add freshly before use: 
  H2O  5 % β-Mercaptoethanol 
add freshly before use:     
1 x Complete® (25x)  Laemmli sample buffer 1x is prepared by  
1 mM PMSF  1:3 dilution of Laemmli sample buffer 3x 
1 % Triton® X-100  with H2O 
 
TBS containing 0.1% Tween  pH 8.0 Tris-CAPS 5x  pH 9.6
24.6 mM Tris  300 mM Tris 
188 mM NaCl  200 mM CAPS 
0.2 % Tween 20    H2O 
  H2O     
 
Anode buffer  Cathode buffer  
12 mM Tris  12 mM Tris 
20 %  Tris-CAPS 5x  20 % Tris-CAPS 5x 
15 % Methanol  0.01 % SDS 
  H2O    H2O 
 
Electrophoresis buffer   
4.9 mM Tris      
38 mM Glycin      
0.1 % SDS      
  H2O      
 
2 Material and methods   - 36 -    
Stacking gel  Separation gel 12,5% 
17.15 % PAA solution 30%  41,6 % PAA solution 30% 
10 % 1,25M Tris pH 6.8  25 % 1.5M Tris pH 8.8 
1 % SDS solution 10%  1 % SDS solution 10% 
0.2 % TEMED   0.1 % TEMED 
1 % APS solution 10%  0.5 % APS solution 
  H2O    H2O 
 
Blotto 5%  BSA 5% 
5 % Blotto  5 % BSA 
  TBS-T pH 8.0    TBS-T  pH 8.0 
 
Coomassie staining solution  Coomassie destaining solution 
3 % Coomassie brilliant blue  10 % Acetic acid (100%) 
10 % Acetic acid (100%)  33 % Ethanol (96%) 
45 % Ethanol (96%)    H2O 
  H2O     
  
ECL solution A  ECL solution B 
25 mM Luminol  0,006 % H2O2
0.396 mM p-Coumaric acid  100 mM Tris  pH 8.5 
100 mM Tris  pH 8.5    H2O 
  H2O      
 
2.4.2 ANTIBODIES 
Table 2:7 Primary antibodies used for western blot analysis. 
primary antibody concentration isotype company 
Akt   1 : 1000 in BSA 5% rabbit IgG Cell Signaling 
Akt phospho  Ser473 1 : 1000 in BSA 5% rabbit IgG Cell Signaling 
IκBα  1 : 1000 in Blotto 5% rabbit IgG Santa Cruz 
IκBα phospho Ser32/Ser36 1 : 1000 in BSA 5% rabbit IgG Cell Signaling 
p38  1 : 1000 in BSA 5% rabbit IgG Cell Signaling 
p38 phospho Thr180/Tyr182 1 : 1000 in BSA 5% rabbit IgG Cell Signaling 
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Table 2:8 Secondary antibodies used for western blot analysis. 
secondary antibody concentration isotype company 
Goat anti mouse 1 : 1000 in Blotto 5% goat IgG1 Biozol 
Goat anti rabbit 1 : 10000 in Blotto 1% goat IgG  Dianova 
 
2.4.3 SAMPLE PREPARATION 
2.4.3.1 PREPARATION OF PROTEIN EXTRACTS FROM MOUSE LIVER TISSUE 
40-60mg of tissue were homogenized in 400-600µl of lysis buffer with a homogenizer  
(Potter S, B. Braun Biotech). After centrifugation of samples (14.000rpm, 4°C, 10 minutes), 
10µl of the supernatants were used for protein concentration determination. 3xSDS Laemmli 
sample buffer was added to the remaining supernatant and probes have been boiled at 95°C 
for 5 minutes. Samples were kept at -20°C until used for Western Blot analysis. 
2.4.3.2 PREPARATION OF PROTEIN EXTRACTS FROM ISOLATED HEPATOCYTES 
Cells were cultured in 6-well plates and were stimulated as described previously  
(chapter 2.2).  Cells were washed twice with ice-cold HBSS following addition of 100µl of 
lysis buffer. Cells have been incubated on ice for 30 minutes, were scraped off and lysates 
were transferred to Eppendorf tubes. After centrifugation (14.000rpm, 4°C, 10 minutes) of the 
homogenates 10µl of the supernatants were used for protein concentration determination. 
3xSDS Laemmli sample buffer was added to the remaining supernatant and probes have 
been boiled at 95°C for 5 minutes. Samples were kept at -20°C until used for Western Blot 
analysis. 
2.4.3.3 PROTEIN CONCENTRATION DETERMINATION 
In order to employ equal amounts of proteins in all samples, protein concentrations were 
determined using the Pierce assay (BC assay reagents, Interdim) as described by Smith and 
colleagues ([166] Smith, 1985). Following 30 minutes of incubation at 37°C, absorbance of 
the blue complex was measured at 550nm (Tecan Sunrise Absorbance reader, Tecan). 
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2.4.4 ELECTROPHORESIS 
Denaturizing SDS–PAGE allows the separation of proteins according to their molecular 
weight.  All proteins were denaturized by addition of SDS, a highly negative charged 
detergent, as described under preparation of protein extracts. Equal amounts of proteins 
were ensured by addition of 1x Laemmli sample buffer. Proteins were loaded and separated 
by SDS-PAGE (Mini PROTEAN 3, Biorad Laboratories). Proteins have been stacked at 100V 
for 21 minutes and separated at 200V for 45 minutes. 
2.4.5 SEMI-DRY BLOTTING 
Following electrophoresis, proteins were transferred from the gels to a PVDF, polyvinylidene 
fluoride, membrane (Immobilon-P, Millipore) by Semi-dry Blotting using a discontinuous 
buffer system. Prior to blotting, the membrane has been washed for 5 minutes in methanol, 
following 30 minutes of incubation in anode buffer. After electrophoresis, gels have been 
washed in cathode buffer for 5 minutes before they were used for Semi-dry Blotting. Proteins 
have been transferred to the membrane at 1,5mA/cm2 for 85 minutes, using the Fastblot B43 
(Biometra). 
2.4.6 PROTEIN DETECTION 
2.4.6.1 SPECIFIC PROTEIN DETERMINATION ON THE MEMBRANE 
Prior to the immunological detection of the relevant proteins, unspecific protein binding sites 
were blocked by incubating the membrane for one hour at room temperature in a 5% Blotto 
solution. Detection of the proteins of interest was performed by incubating the membrane 
with the appropriate specific primary antibody overnight at 4°C with continuous shaking. After 
four washing steps with TBS-T (2 x 30 seconds, 2 x 10 minutes), the membrane has been 
incubated with the secondary antibody for 1 hour, following 4 additional washing steps (2 x 
30 seconds, 2 x 10 minutes). For detection of proteins, the membrane has been incubated in 
a 1:1 mixture of ECL solution A and solution B for 2 minutes. Luminescence detection was 
performed by exposure of the membrane to a medical X-ray film (Fuji) and subsequent 
development with a Curix 60 developing system (Agfa-Gevaert N.V.). Quantification was 
performed with a Kodak image station (NEN). 
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2.4.6.2 UNSPECIFIC PROTEIN STAINING WITH COOMASSIE BLUE 
In order to ensure equal loading of proteins and uniform blotting of all samples, gels have 
been stained with Coomassie brilliant blue solution for 20 minutes. The solution nearly stains 
all kinds of proteins without any specification. Afterwards Gels have been washed for 1 hour 
with destaining solution. Proteins became visible as blue bands. 
 
2.5 EMSA – ELECTRO MOBILITY SHIFT ASSAY 
Electro mobility shift assay (EMSA) was used to determine NF-κB transcription factor activity, 
by analyzing its ability to form NF-κB-DNA complexes. 
2.5.1 MATERIAL AND SOLUTIONS 
Table 2:9  Material used for electro mobility shift assay. 
product   company 
[γ32P]-ATP 3000Ci/mmol  Amersham 
Nuc Trap probe purification columns  Stratagene 
T4 polynucleotide kinase  USB 
 
Buffer A  Buffer B 
10 mM Hepes pH 7.9  20 mM Hepes pH 7.9
10 mM KCl  400 mM NaCl 
0.1 mM EDTA  1 mM EDTA 
0.1 mM EGTA  0.5 mM EGTA 
  H2O  25 % Glycerol 
add freshly before use:    H2O 
1 mM DTT  add freshly before use: 
0.5 mM PMSF  1 mM DTT 
    1 mM PMSF 
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STE buffer pH 7.5 Binding buffer 5x 
10 mM Tris  20 % Glycerol 
100 mM NaCl  5 mM MgCl2
1 mM EDTA  2.5 mM EDTA 
  H2O  250 mM NaCl 
    50 mM Tris-HCl 
      H2O 
 
Reaction buffer  Gel loading buffer 
90 % Binding buffer 5x  250 mM Tris-HCl 
10 % Gel loading buffer  0.2 % Bromphenolblue 
2.6 mM DTT  40 % Glycerol 
  H2O   H2O 
 
Non-denaturizing PAA  gel  TBE 10x pH 8.3
5.3 % TBE 10x  890 mM Tris 
15.8 % PAA solution 30%  890 mM Boric acid 
2.6 % Glycerol  20 mM EDTA 
0.05 % TEMED    H2O 
0.08 % APS     
  H2O     
 
2.5.2 RADIOACTIVE LABELING OF CONSENSUS OLIGONUCLEOTIDES 
Double-stranded oligonucleotides containing the consensus sequence for NF-κB 5’- AGT 
TGA GGG GAC TTT CCC AGG C -3’ (Promega) was 5’ end-labeled with [γ32P]-ATP using 
the T4 polynucleotide kinase which catalyzes the transfer of the radioactive phosphate to the 
5’ hydroxyl site of the DNA. After incubation of oligonucleotides with T4 kinase for 10 minutes 
at 37°C, the reaction was terminated by addition of 0.5M EDTA solution. The radioactive 
labeled DNA was separated from unlabeled DNA by using Nuc Trap probe purification 
columns. Radioactive oligonucleotides were eluted from the column with 70µl of STE buffer 
and frozen at -20°C until used for electro mobility shift assay. 
2 Material and methods - 41 - 
2.5.3 SAMPLE PREPARATION 
2.5.3.1 PREPARATION OF NUCLEAR EXTRACTS FROM MOUSE LIVER TISSUE 
Tissue samples were prepared with a homogenizer (Potter S, B. Braun Biotech) by 
homogenizing the probes in Buffer A. After centrifugation (1000rpm, 10 minutes, 4°C) and 
incubation at 4°C for 10 minutes in 300µl freshly added Buffer A containing 18µl of NP-40 
10%, probes were centrifuged (14000rpm, 10 minutes, 4°C). The supernatant has been 
removed and the pellet was suspended in Buffer B, following incubation at 4°C for 30 
minutes with continuous shaking. After centrifugation (14000prm, 10 minutes, 4°C) 
supernatants were frozen at -80°C and nuclear proteins were kept until used for protein 
quantification and EMSA. 
2.5.3.2 PREPARATION OF NUCLEAR EXTRACTS FROM ISOLATED HEPATOCYTES 
Nuclear extracts were prepared from either untreated or stimulated hepatocytes. Following 
stimulation, cells were scraped on ice after washing twice with ice-cold HBSS buffer. In order 
to gain a useable amount of nuclear protein, three wells were combined, each containing 
200µl of HBSS buffer. After centrifugation (1500rpm, 5 minutes, 4°C), the supernatant was 
discarded and 400µl of buffer B was added to the remaining pellet. Samples have been 
incubated at 4°C for 15 minutes, 25µl NP-40 10% were added and samples were centrifuged 
(12000rpm, 1 minute, 4°C) immediately. The supernatant was removed and the remaining 
pellet was suspended in 50µl Buffer B. Probes have been incubated at 4°C for 15 minutes 
with continuous shaking. After centrifugation (12000rpm, 5 minutes, 4°C) supernatants were 
frozen at -80°C and nuclear proteins were kept until used for protein quantification and 
electro-mobility shift assay (EMSA). 
2.5.3.3 PROTEIN CONCENTRATION DETERMINATION 
Protein concentrations in isolated nuclear protein fractions were determined by the method of 
Bradford ([25] Bradford, 1976) using Coomassie brilliant blue G250. Absorbance of the 
samples was measured at 590nm (Tecan Sunrise Absorbance reader, Tecan). 
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2.5.4 BINDING REACTION AND ELECTROPHORETIC SEPARATION 
To ensure equal amounts of proteins, 5µg of protein were provided in a total amount of 14µl, 
containing 2µg poly(dIdC) and 3µl of freshly prepared reaction buffer. Samples have been 
incubated for 10 minutes at room temperature. To start NF-κB – DNA binding reaction, 1µl of 
the radioactive labeled oligonucleotide was added and samples were left for 30 minutes at 
room temperature. The protein-oligonucleotide complexes have been separated by gel 
electrophoresis (Mini-Protean 3, BioRad) with 0.25 x TBE buffer at 100V for 60 minutes using 
non-denaturizing polyacrylamide gels. 
2.5.4.1 CONTROL EXPERIMENTS 
Parallel to each experiment a positive and negative control experiment has been performed 
in order to ensure specific oligonucleotide-transcription-factor binding. Therefore, different 
unlabeled oligonucleotides were added to the specific samples; 
⇒ positive control NF-κB:  - unlabelled AP-1 oligonucleotide was added ⇒ signal   
⇒ negative control NF-κB: - unlabelled NF-κB oligonucleotide was added ⇒ no signal. 
Now, we are able to determine specific and unspecific protein binding. In the case of 
unlabeled AP-1 oligonucleotide addition, NF-κB should still quantitatively bind to its 
corresponding labelled NF-κB oligonucleotide. Therefore, the same signal as previously seen 
without addition of AP-1 oligonucleotide is supposed to appear. For negative control, the NF-
κB signal is mainly supposed to be blocked because of additional binding of NF-κB to the 
unlabeled NF-κB oligonucleotide. Representative for all performed EMSA experiments, both 
types of control experiments are once demonstrated in (Figure 3:16). 
Additionally “free probe” resulting from the great excess of unbound radioactive 
oligonucleotide has been detected in each experiment. One representative example is shown 
in (Figure 3:18). 
2.5.5 DETECTION AND EVALUATION 
Following electrophoresis, gels have been exposed to Cyclone Storage Phosphor Screens 
(Canberra-Packard) for 24 hours, followed by analysis with a phosphor imager station 
(Cyclone Storage Phosphor System, Canberra-Packard). 
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2.6 HISTOLOGICAL ANALYSIS 
Histological analysis was performed to determine changes in localization and presence of 
different proteins. We have mainly been interested in LPS-induced translocation of the  
NF-κB subunit p65 into the nucleus. Therefore, histological analysis has been performed by 
staining murine liver macrophages, the cell nucleus and the NF-κB subunit p65. 
2.6.1 MATERIAL AND SOLUTIONS  
Table 2:10 Material used for histological analysis. 
product   company 
Coverplate™  Thermo Shandon GmbH 
Mounting medium  Dako Cytomation GmbH 
 
PBS pH 7.4  1% BSA solution 
10.4 mM Na2HPO4 1 % BSA 
3.16 mM KH2PO4  PBS 
132.2 mM NaCl   
  H2O   
 
2.6.2 ANTIBODIES 
The following antibodies were used for immune-histochemical analysis. Antibody dilutions 
have always been freshly prepared before administration. Secondary antibodies were always 
carefully kept away from light, and therefore, incubated in the dark. 
Table 2:11 Primary antibodies used for histological analysis. 
primary antibody concentration isotype company 
NF-κB p65 1 : 100 in 0.2% BSA in PBS rabbit IgG Santa Cruz 
F4/80 1 : 100 in 0.2% BSA in PBS rat IgG Caltag 
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Table 2:12 Secondary antibodies used for histological analysis. 
secondary antibody concentration isotype company 
Alexa Fluor®488 anti-rat 1 : 400 in 0.2% BSA in PBS goat IgG  Molecular Probes 
Alexa Fluor®647 anti-rabbit 1 : 400 in 0.2% BSA in PBS chicken IgG Molecular Probes 
Hoechst 33342 dye 5µg/ml in 0.2% BSA in PBS  Sigma 
 
2.6.3 HISTOLOGICAL ANALYSIS OF LIVER TISSUE 
2.6.3.1 IMMUNHISTOCHEMISTRY 
Snap frozen organs were cut into 8µm sections, placed on glass slides, and have been fixed 
immediately in 3% formaldehyde for 3 minutes.  Afterwards, slides were washed in PBS.  
Glass slides were carefully placed in slide holder (Coverplate) and rinsed two times with PBS 
to ensure that the entire slide is equally moistened. Fixed tissue has been blocked with 1% 
BSA solution and tissues have subsequently been incubated with primary and secondary 
antibody for 1 hour at room temperature. Following each step any remaining substances 
were removed by extensive PBS washing. After antibody incubation, slides were washed 
twice with PBS and 100µl of Hoechst staining has been applied for 5 minutes, following an 
additional washing step. Finally, organ sections have been covered with mounting medium, 
dried for 24 hours and analyzed by confocal laser scanning microscopy. 
2.6.3.2 TUNEL STAINING AND INFILTRATION OF LEUKOCYTES 
DNA fragmentation is one major sign of apoptotic cell death. To determine strand brakes of 
genomic DNA, formalin fixed tissue samples were embedded in paraffin, and 5µm sections 
were cut. These sections were analyzed using the terminal desoxynucleotide transferase-
mediated dUTP nick end labelling (TUNEL) assay. TUNEL staining was kindly performed by 
Dr. Herbert Meissner and Andrea Sendlhofer (Institute of Pathology, Ludwig-Maximilians 
University, Munich, Germany). Liver sections were stained as described previously ([57] 
Gerwig, 2003).   
Haematoxylin and eosin staining for leukocyte infiltration was kindly performed by Dr. Herbert 
Meissner and Andrea Sendlhofer (Institute of Pathology, Ludwig-Maximilians University, 
Munich, Germany). Liver sections were stained as described previously ([57] Gerwig, 2003). 
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2.7 REAL TIME RT-PCR 
Real time RT-PCR is a method used to quantify different mRNA amounts of certain genes. 
RNA is translated into cDNA, following cDNA replication. Continuant measurement of cDNA 
amount occurs during cDNA replication. 
2.7.1 MATERIAL AND SOLUTIONS 
TBE buffer  Agarose gel 1.2%
89 mM Tris 1.2 % Agarose 
89 mM Boric acid  0.01 % Ethidiumbromide  
0.5 mM Na2EDTA  TBE buffer  
  H2O   
 
Table 2:13  Primer sequences used for real time RT-PCR analysis. 
primer species sequence 
TNF-α1  forward primer mouse 5’-tgg cct ccc tct cat cag ttc-3’  
TNF-α 1 reverse primer mouse 5’-ttg gtg gtt tgc tac gac gtg-3’  
TNF-α1 TaqMan probe mouse FAM 5’-tggcccagaccctcacactcagatcatc-3’ BHQ 
      
HPRT1 forward primer mouse 5’-gtt aag cag tac agc ccc aaa atg-3’  
HPRT1 reverse primer mouse 5’-aaa tcc aac aaa gtc tgg cct gta-3’  
HPRT1 TaqMan probe mouse HEX 5’-agc ttg ctg gtg aaa agg acc tct cga agt-3’ BHQ
      
TNF-α2 forward primer human 5'-cca ggc agt cag atc atc ttc tc-3'  
TNF-α2 reverse primer human 5'-agc tgg tta tct ctc agc tcc ac-3'  
GAPDH forward primer human 5’-ggg aag gtg aag gtc gga gt-3’  
GAPDH reverse primer human 5’-tcc act tta cca gag tta aaa gca g-3’  
1  ([108] Lambertsen, 2005)  
2  Med. 2, Universitätsklinikum Großhadern, 81377 Munich 
The relevant complete mRNA sequences are listed in chapter 5.1.
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2.7.2 SAMPLE PREPARATION 
2.7.2.1 RNA PREPARATION FROM ORGAN SAMPLES AND HEPATOCYTES 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen) according to the instruction 
manual. In order to guarantee efficient RNA extraction a few steps were added. After 
disruption of the tissue, homogenization is necessary to reduce the “viscosity” of the lysates. 
Therefore, the disrupted samples were loaded onto a QIAshredder Spin Column and spun 
down (14000rpm, 2 minutes, 20°C). Real time RT-PCR is very sensitive to small amounts of 
DNA.  We used the RNase Free DNase Set for digestion of DNA during RNA purification. All 
additional materials were applied following the users instructions manual. RNA samples were 
kept at -80°C until used for real time RT-PCR. 
2.7.2.2 RNA PREPARATION FROM WHOLE BLOOD SAMPLES 
Total RNA was extracted using the RNeasy Mini blood kit from Qiagen according to the 
instruction manual. Real time RT-PCR is very sensitive to small amounts of DNA.  We used 
the RNase Free DNase Set for digestion of DNA during RNA purification. All additional 
materials were applied following the users manual instructions. RNA samples were kept 
at -80°C until used for real time RT-PCR. 
2.7.2.3 DETERMINATION OF RNA CONTENT AND RNA INTEGRITY 
After RNA elution from the QIAamp Spin Column, 10µl were diluted in 490µl of water and 
RNA content was determined by measuring the absorption at 260nm and 280nm. The RNA 
content was calculated from the A260 value. The A260/A280 ratio was used to determine the 
RNA purity. Integrity of isolated RNA was checked subjecting 1µg of total RNA to agarose 
gel electrophoresis (described under 2.7.4.3). 
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2.7.3 REVERSE TRANSCRIPTION 
Reverse transcription was performed with the DyNAmo Probe 2-Step qRT-PCR Kit. A 
minimum of 400ng and a maximum of 1000ng isolated RNA were transcribed into cDNA 
according to the users’ manual instructions. 
Table 2:14 Cycling protocol for reverse transcription into cDNA. 
purpose temperature time 
primer extension 25°C 10 minutes 
cDNA synthesis 37°C 45 minutes 
reaction termination 85°C 5 minutes 
 
2.7.4 REAL TIME RT-PCR 
Real time RT-PCR analysis has always been accomplished according to the DyNAmo Probe 
2-Step qRT-PCR Kit users manual. Features that were previously individualized are listed 
below within the accordant chapter, 2.7.4.1 and 2.7.4.2. 
2.7.4.1 PROBE REAL TIME RT-PCR 
Real time RT-PCR was performed with the DyNAmo Probe 2-Step qRT-PCR Kit. Real time 
RT-PCR was accomplished with 100nmol/l probe and 400nmol/l of each forward and reverse 
primer. 10% of the final mixture was provided by the cDNA sample, which contained 
20ng – 100ng cDNA, which has been calculated as RNA. The HPRT1 gene was used as an 
internal housekeeping gene to normalize the TNF-α data set. 
Table 2:15  Cycling protocol for probe real time RT-PCR analysis. 
purpose temperature time  
initial denaturizing 95°C 15 minutes  
denaturizing 95°C 15 seconds 
annealing and extension 60°C 60 seconds 
 
45 cycles
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2.7.4.2 SYBR-GREEN REAL TIME RT-PCR 
Real time RT-PCR was performed with the DyNAmo Probe 2-Step qRT-PCR Kit. Real time 
RT-PCR was accomplished by addition of SYBR-green solution (0.2x final concentration) 
and 400nmol/l of each forward and reverse primer into the given Master-mix. The GAPDH 
gene was used as an internal housekeeping gene to normalize the TNF-α data set. 
Table 2:16 Cycling protocol for SYBR-green real time RT-PCR analysis. 
purpose temperature time  
initial denaturizing 95°C 15 minutes  
denaturizing 95°C 30 seconds 
annealing 55°C 30 seconds 
 
extension 72°C 30 seconds  
final extension 72°C 10 minutes  
melting curve 60°C - 95°C   
45 cycles
 
2.7.4.3 PRODUCT DETERMINATION 
In order to check for primer dimers and secondary PCR products, all samples were 
separated by agarose gel electrophoresis (Owl separation Systems). Ethidiumbromide 
agarose gels were prepared as described previously (2.7.1). PCR products were 
supplemented with 6x blue/orange loading dye, loaded onto an agarose gel and 
electrophoresis has been performed for 2 hours at 100V. Fluorescence of the PCR products 
was visualized with a Kodak image station (Kodak) at 254nm. Following SYBR-green real 
time RT-PCR a melting curve has been generated, ranging from 60°C to 95°C. Calculation of 
the mRNA content was performed with a new mathematical model for relative quantification 
of real time PCR products developed by Pfaffl and colleagues ([149] Pfaffl, 2001). 
 
 
2 Material and methods - 49 - 
2.8 FACS ANALYSIS 
Flow cytometry is a useful method for the measurement of cell size and granularity as well as 
the detection of fluorescent stains. Therefore, we used FACS analysis to determine total 
TNF-α protein expression in human and mouse whole blood leukocytes as well as on 
leukocyte cell-surface. 
2.8.1 MATERIAL AND SOLUTIONS 
Table 2:17 Material used for FACS analysis. 
product   company 
FACS™ Lysing solution Becton Dickinson 
BD Cytofix/Cytoperm™ Plus Kit with GolgiPlug™ BD Biosciences 
 
FACS buffer pH 7.37  PBS pH 7.4
140 mM NaCl 10.4 mM Na2HPO4
1.9 mM KH2PO4 3.16 mM KH2PO4
16.5 mM Na2HPO4 132.2 mM NaCl 
3.8 mM KCl  H2O 
1 mM EDTA   
10.2 mM LiCl   
3 mM NaN3   
  H2O   
 
2.8.2 ANTIBODIES 
Table 2:18 Primary antibodies used for FACS analysis. 
primary antibody concentration isotype supplier 
TNF-α human 1 : 100 in PBS1 rabbit IgG Endogen 
TNF-α mouse 1 : 100 in PBS1 rabbit IgG Endogen 
1 After permeabilization of cells, BD Perm/Wash solution has carefully been used for antibody  
  dilutions to keep cells permeabilized. 
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Table 2:19 Secondary antibodies used for FACS analysis. 
secondary antibody concentration isotype company 
Alexa Fluor®488 anti rabbit 1 : 400 in PBS1 goat IgG  Molecular Probes 
1 After permeabilization of cells, BD Perm/Wash solution has carefully been used for antibody  
  dilutions to keep cells permeabilized. 
 
2.8.3 IMMUNOLOGICAL STAINING OF WHOLE BLOOD LEUKOCYTES 
The evaluation of TNF-α expression was carried out using the FACS Lysing solution for lysis 
of erythrocytes, BD Cytofix/Cytoperm plus Kit for permeabilization of cells, following anti 
TNF-α staining of whole blood leucocytes. At the end of the stimulation period, cells were 
pulled down by centrifugation (3500rpm, 10 minutes, 4°C).  Supernatants were discarded 
and the remaining pellets have been suspended in FACS Lysing Solution for 10 minutes in 
the dark. Cave! Careful fixation had to be provided to prevent permeabilization during 
cytokine staining when cell surface had to be determined.  After centrifugation (2130rpm, 5 
minutes, 4°C), supernatants were removed, cells were suspended in the remaining fluid and 
PBS was used for intensive washing. Washing and centrifugation steps were handled as far 
as necessary between each treatment. If indicated, cells have been permeabilized using BD 
Cytofix/Cytoperm plus Kit following the users’ instructions manual. Afterwards, cells have 
been incubated with anti TNF-α antibody for 60 minutes, following Alexa Fluor 488 labeled 
secondary antibody incubation. Finally, cells were diluted in 500µl PBS and TNF-α 
expression was determined by FACS analysis. 
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2.8.4 DETECTION 
The FACS instrument settings were adjusted with control cells primarily stained with TNF-α 
following Alexa Flour 488 staining. The fluorescence of previously-bound labeled antibody 
can be analyzed in the FL-1 channel (λem: 530nm), where increased antibody binding results 
in changes of fluorescence intensity. In order to analyze different cell-types, populations  
(a: monocytes; b: neutrophils) were gated and analyzed separately. The median (FL1-H) of 
the curve was used to determine relative TNF-α amounts (Figure 2:4). 
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Figure 2:4 Evaluation of FACS analysis measurements. 
2.9 STATISTICAL ANALYSIS 
All cell-experiments were performed at least three times unless indicated otherwise in the 
respective figure legend. Animal experiments were performed using the accordant number of 
animals, as shown in the respective table in chapter 2.1. Results are shown as mean ± SEM. 
Statistical analysis was performed using the GraphPad Prism 3.03 software (GraphPad 
software Inc). Significance (*) has always been calculated at the 95% confidence interval in 
comparison to its corresponding control experiment, unless indicated otherwise in the 
respective figure legend. Because of post-developmental changes, neither western blot 
analysis nor histological analysis is subjected to any evaluation of significance. 
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3.1 RESEARCH BACKGROUND 
Before starting our investigations, a lot of research had already been done in the past. 
Thereby, the effects of ANP preconditioning on survival of animals suffering from LPS-
induced septic shock have quite recently been investigated. Administration of LPS caused an 
immediate change of animals’ state of health. This was observed in LPS as well as in 
ANP/LPS treated mice. LPS treated animals with administration of ANP initially showed 
worsening of their state of health but soon recovered from symptoms of LPS-induced septic 
shock. All animals without ANP preconditioning died within 25 hours. Mice preconditioned 
with ANP survived LPS-induced septic shock by 75%, as shown in Figure 3:1-A.   
TNF-α concentration in blood is an important marker in LPS-induced septic shock ([118] Lin, 
2005). Thus, it had been interesting, whether survival after ANP preconditioning is 
associated with changes in TNF-α expression. Cytokine concentration had been determined 
in plasma 90 minutes after LPS injection. At this point, TNF-α levels in LPS stimulated 
animals peaked and were detected by ELISA. As shown in Figure 3:1-B, preconditioning with 
the cardiovascular hormone ANP caused a significant decrease in TNF-α serum levels by 
80% in LPS treated mice. All research has been done by Melanie Keller up to this point ([91] 
Keller, 2005a). 
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Figure 3:1 ANP improves survival of mice treated with LPS and reduces TNF-α concentration in serum 
90 minutes after LPS injection. Mice were injected NaCl (control and LPS group) or ANP (ANP 
and ANP/LPS group). 20 minutes after first injection mice received NaCl (control and ANP 
group) or LPS (LPS and ANP/LPS group). The animal’s state of health had been continuously 
observed for 72 hours (A). 90 minutes after LPS injection, blood was withdrawn from the heart 
and used for TNF-α concentration determination by ELISA (B). 
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3.2 SEPTIC SHOCK MODEL 
As described in the previous chapter, pretreatment with ANP significantly reduces mortality in 
septic shock, which is associated with changes in plasma TNF-α concentrations. Therefore, 
it has to be investigated, how ANP contributes to minor TNF-α  plasma levels in septic mice. 
3.2.1 INFLUENCE OF ANP ON LPS-INDUCED TNF-α mRNA EXPRESSION 
In order to investigate mechanisms leading to the protective effects of ANP, TNF-α 
expression in various organs had to be determined. Therefore, we examined mRNA TNF-α 
expression in selected organs – liver (3.2.1.1), spleen (3.2.1.2) and heart (3.2.1.3). Changes 
in TNF-α plasma concentrations have primarily been detectable 90 minutes after LPS-
induced septic shock. On account of this, we focused on this time point and the previous time 
point, 30 minutes after LPS injection, to determine TNF-α mRNA expression. To ensure 
primarily equal cDNA amounts, the hypoxanthine-guanine-posphoribosyl transferase (HPRT) 
gene was used to normalize the TNF-α data set. As seen in Figure 3:2, TNF-α ct-values  
(ct -cycle of threshold) derived from LPS treated mice are lower than TNF-α ct-values in 
organs of untreated animals. HPRT gene expression is completely unaffected by LPS 
injection, resulting in equal HPRT-ct values for all animals. 
1 405 10 15 20 25 3530
cycle
threshold
co
LPS
TNF-α
1 -
0.1 -
0.001 -
10 -
0.01 -
ct
1 45 10 15 20 25 3530
cycle
threshold
co & LPS
0
HPRT
0.1 -
0.01 -
0.001 -
1 -
ct
RnRn
 
Figure 3:2 LPS stimulation influences TNF-α gene expression in different organs in mice. Organ samples 
of NaCl (co) or LPS treated mice were obtained 90 minutes after LPS injection. Whole liver 
homogenates were analyzed by real time RT-PCR. Illustrations are demonstrating cDNA 
replication curves for TNF-α (left) and HPRT (right). Graphs are showing one representative 
example, with four animals out of five. 
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3.2.1.1 TNF-α mRNA EXPRESSION IN MOUSE LIVER 
The liver is the largest organ in the abdomen. Most bacteria that enter 
the organism within the blood stream are taken up and eliminated by 
the liver. Resident liver macrophages, also denoted as Kupffer cells, 
constitute the largest compartment of tissue macrophages present in 
the body. They are the first cell population to come in contact with bacteria, bacterial 
endotoxins and microbial debris ([63] Gregory, 2002b). Therefore, we were interested in 
changes of TNF-α mRNA expression in livers of ANP pretreated septic mice. Mice have 
been treated as described previously (2.1.3) and classified into different groups (control, 
ANP, LPS, ANP/LPS). As shown in Figure 3:3, LPS treatment rapidly accelerates TNF-α 
mRNA expression, already seen 30 minutes after injection, which steadily consists until the 
time point of 90 minutes. ANP preconditioning significantly reduces this TNF-α mRNA 
augmentation by 60% as soon as 30 minutes after LPS injection. Interestingly, this strong 
reduction has totally been abrogated 90 minutes after LPS-induced septic shock. 
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Figure 3:3 ANP preconditioning contributes to TNF-α mRNA reduction after LPS-induced septic shock in 
whole liver homogenates. Animals were preconditioned with ANP (ANP/LPS group) 15 
minutes previous to LPS (LPS group) injection. Mice, only receiving NaCl (control group) or 
ANP (ANP group) were used to identify an impact of these substances on TNF-α mRNA 
expression.  Organ samples were obtained 30 and 90 minutes after LPS injection. Whole liver 
homogenates were analyzed by real time RT-PCR. Graphs are showing determined TNF-α  
mRNA expression 30 minutes (left) and 90 minutes (right) after LPS injection. Graphs are 
representing all animals analyzed for each group including five mice.  Real time RT-PCR 
analysis has been performed in duplicate. 
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3.2.1.2 TNF-α mRNA EXPRESSION IN MOUSE SPLEEN 
The spleen is the bodies’ largest filter of the blood. Within this organ innate and adaptive 
immune system are combined. Therefore, the spleen is the most important organ for 
antimicrobial reactivity ([130] Mebius, 2005). Thus, we were interested in changes of TNF-α 
mRNA expression in spleens of ANP pretreated septic mice. Similar to the results 
determined in whole liver homogenates, LPS injection subsequently leads to elevated TNF-α 
mRNA expression in the spleen as soon as 30 minutes after LPS administration (Figure 3:4). 
ANP preconditioning yields 40% - 50% reduction of LPS-induced TNF-α mRNA expression 
at both investigated time points. 
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Figure 3:4  ANP preconditioning contributes to TNF-α mRNA reduction after LPS-induced septic shock in 
whole spleen homogenates. Animals were preconditioned with ANP 15 minutes (ANP/LPS 
group) previous to LPS (LPS group) injection. Mice, only receiving NaCl (control group) or 
ANP (ANP group) were used to identify an impact of these substances on TNF-α mRNA 
expression. Organ samples were obtained 30 and 90 minutes after LPS injection. Whole 
spleen homogenates were analyzed by real time RT-PCR. Graphs are showing determined 
TNF-α mRNA expression 30 minutes (left) and 90 minutes (right) after LPS injection. Graphs 
are representing all animals analyzed, each group consisting of five mice.  Real time RT-PCR 
analysis has been performed in duplicate. 
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3.2.1.3 TNF-α mRNA EXPRESSION IN MOUSE HEART 
The polypeptide hormone, atrial natriuretic peptide, is primarily produced in the atrial 
cardiocytes of the heart ([129] McGrath, 2005). Being the main organ of ANP synthesis, we 
were interested in changes of TNF-α mRNA expression in the heart of ANP pretreated septic 
mice. As shown in Figure 3:5, in mice hearts, LPS injection subsequently leads to significant 
TNF-α mRNA expression as soon as 30 minutes after LPS administration. Interestingly, ANP 
preconditioning does not have any influence on LPS-induced TNF-α mRNA expression 
neither 30 minutes nor 90 minutes after LPS injection. 
 
control ANP LPS ANP/LPS
0
25
50
75
100
125
150
* *
n.s.
%
control ANP LPS ANP/LPS
0
25
50
75
100
125
150
* *
n.s.
%
m
-R
N
A 
ra
tio
 in
 %
m
-R
N
A 
ra
tio
 in
 %
30’ 90’
% %
m
-R
N
A 
ra
tio
 in
 %
m
-R
N
A 
ra
tio
 in
 %
% %% %
m
-R
N
A 
ra
tio
 in
 %
m
-R
N
A 
ra
tio
 in
 %
 
Figure 3:5 ANP preconditioning does not contribute to TNF-α mRNA reduction after LPS-induced septic 
shock in whole heart homogenates. Animals were preconditioned with ANP 15 minutes 
(ANP/LPS group) previous to LPS (LPS group) injection. Mice, only receiving NaCl (control 
group) or ANP (ANP group) were used to identify an impact of these substances on TNF-α 
mRNA expression.  Organ samples were obtained 30 and 90 minutes after LPS injection. 
Whole heart homogenates were analyzed by real time RT-PCR. Graphs are showing 
determined TNF-α mRNA expression 30 minutes (left) and 90 minutes (right) after LPS 
injection. Graphs are representing all animals analyzed, each group consisting of five mice.  
Real time RT-PCR analysis has been performed in duplicate. 
 
3 Results   - 58 -    
3.3 THE LIVER 
3.3.1 CHANGES IN LIVER TISSUE 
Due to the fact that TNF-α mRNA expression has significantly been reduced in liver tissue, 
we focused on this organ in order to determine the signaling pathways responsible for TNF-α 
mRNA and cytokine reduction. In our model of LPS-induced septic shock, the latest time 
point we are focusing on is 90 minutes of LPS treatment. Therefore, we were interested in 
morphological changes in liver tissue as far as to this moment. 
3.3.1.1 TUNEL STAINING OF APOPTOTIC CELLS 
Apoptotic cell death was determined by biochemical and morphological techniques in order 
to identify early cell damage in the liver during septic shock. DNA fragmentation is one major 
sign of apoptotic cell death. To determine strand brakes of genomic DNA, formalin fixed 
tissue samples were embedded in paraffin, and 5µm sections were cut. These sections were 
analyzed using the terminal desoxynucleotide transferase-mediated dUTP nick end labelling 
(TUNEL) assay (Figure 3:6). Morphological criteria of apoptosis in TUNEL stained 
hepatocytes were cell shrinkage and the occurrence of apoptotic bodies. TUNEL staining of 
90 minutes LPS treated liver sections did not show any increase in TUNEL positive 
hepatocytes (a) with characteristic pathologic signs of apoptosis. 
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3.3.1.2 INFILTRATION OF LEUKOCYTES 
After investigating characteristic signs of apoptosis, we have been interested in leukocyte 
infiltration in liver tissue. The infiltration of leukocytes was determined by Haematoxylin and 
Eosin (HE) staining (Figure 3:7) of formalin fixed, paraffin embedded liver tissue. Staining of 
livers derived from 90 minutes LPS treated mice did not display any significant evidence of 
cell injury and leukocyte infiltration. Interestingly, leukocyte infiltration into the liver could 
neither been determined in liver tissue around the central vein (left) nor the portal vein (right) 
as far as to this moment. 
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3.3.2.1 AKT PROTEINKINASE REGULATION 
The PI3 kinase/Akt kinase pathway is known to participate in signaling cascades during 
inflammation in different cell types. In order to investigate whether ANP pretreatment in 
septic mice has an influence on proteinkinase Akt activation, we focused on kinase 
phosphorylation 15, 30, and 90 minutes after LPS injection. Whole liver homogenates were 
analyzed by western blot and Akt phosphorylation (Ser473) has been determined by specific 
antibody binding. As presented in Figure 3:8, following LPS injection, mice displayed a strong 
increase in Akt phosphorylation as soon as 15 minutes after LPS administration. This 
phosphorylation status clearly increases until 30 minutes of LPS treatment. In regard to the 
phosphorylated amount detected 30 minutes after LPS administration, phosphorylation 
decreases to the time point of 90 minutes. In all experiments, the phosphorylation status has 
been evaluated in according to its corresponding control group at the chosen time point. 
Phosphorylation slightly changes in control animals most likely due to the influence of stress 
during the animal experiments. The results displayed in Figure 3:9 obviously demonstrate 
that ANP pretreatment decreases LPS-induced Akt phosphorylation at all determined time 
points. These effects lead to the assumption of Akt kinase involvement in ANP mediated 
protection from LPS-induced septic shock. 
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Figure 3:8 Time dependent Akt kinase phosphorylation in whole liver homogenates 15, 30, and 90 
minutes after LPS injection. Western blot analysis was performed detecting phosphorylated 
(pAkt) and total (totAkt) amounts of Akt kinase. In further experiments, each phosphorylation 
status has been evaluated in relation to its corresponding control group (NaCl treatment) at 
the same time point (15 and 90 minutes shown). The figure shows 3 representative animals of 
each group out of 5 animals.  Western blot analysis has been performed in duplicate. Western 
blot membranes for total amounts of Akt kinase (totAkt) are shown to ensure equal protein 
loading. 
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Figure 3:9 ANP preconditioning decreases LPS-induced Akt phosphorylation in whole liver homogenates. 
Animals were preconditioned with ANP (ANP/LPS group) 15 minutes previous to LPS (LPS 
group) injection. Mice, only receiving NaCl (control group) or ANP (ANP group) were used to 
identify an impact of these substances on Akt kinase phosphorylation.  Organ samples were 
obtained 15, 30, and 90 minutes after LPS injection. Whole liver homogenates were analyzed 
by western blot. Graphs are showing determined Akt phosphorylation 15 minutes (top), 30 
minutes (middle) and 90 minutes (bottom) after LPS injection. Western blots are representing 
2 animals out of each group consisting of five mice.  Western blot membranes for total 
amounts of Akt kinase (totAkt) are shown to ensure equal protein loading. Western blot 
analysis has been performed in duplicate. 
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3.3.2.2 p38 PROTEINKINASE REGULATION 
Not only the PI3 kinase/Akt pathway, but also the p38 MAPK signaling pathway has 
frequently been described to be involved in signaling cascades during LPS-induced 
inflammation and septic shock ([3] Akira, 2004). Therefore, we were interested in the ANP 
mediated effects on p38 MAPK phosphorylation. Whole liver homogenates were analyzed by 
western blot techniques and p38 MAPK phosphorylation has been determined by specific 
antibody binding. The employed antibody determines both required phosphorylation sites 
(Thr180/Tyr182) for p38 MAPK activation. Following LPS injection, animals displayed a 
strong decrease in p38 MAPK phosphorylation status already detectable 15 minutes after 
LPS administration. The reduced p38 MAPK phosphorylation persists until 30 minutes after 
LPS administration. As displayed in Figure 3:10, the reduced phosphorylation of p38 MAPK 
still exists but slightly increases 90 minutes after LPS injection in regard to 15 and 30 
minutes  LPS treated analyzed liver homogenates. During experiments the phosphorylation 
status has been evaluated in relation to its corresponding control group at the chosen time 
point. The influence of ANP pretreatment on the phosphorylation of p38 MAPK is shown in 
Figure 3:11. ANP pretreatment does not seem to have any influence on LPS-induced 
decrease in p38 MAPK phosphorylation at all determined time points. Conclusively, p38 
MAPK might be involved in LPS mediated inflammatory signaling pathways, whereas ANP 
preconditioning does not interfere with these effects. 
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Figure 3:10 Time dependent p38 proteinkinase phosphorylation in whole liver homogenates 15, 30, and 
90 minutes after LPS injection. Western blot analysis was performed detecting phosphorylated 
and total amounts of the proteinkinase p38 MAPK. In further experiments, each 
phosphorylation status has been evaluated in response to its corresponding control group 
(NaCl treatment) at the same time point (15 and 90 minutes shown). The figure shows three 
representative animals out of five animals in each group.  Western blot analysis has been 
performed in duplicate. 
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Figure 3:11 ANP preconditioning does not influence LPS-induced decreased p38 MAPK phosphorylation 
in whole liver homogenates. Animals were preconditioned with ANP (ANP/LPS group) 15 
minutes previous to LPS injection (LPS group). Mice only receiving NaCl (control group) and 
ANP (ANP group) were used to identify an impact of these substances on p38 MAPK 
phosphorylation.  Organ samples were obtained 15, 30, and 90 minutes after LPS injection. 
Whole liver homogenates were analyzed by western blot. Graphs are showing determined p38 
MAPK phosphorylation (pp38) 15 minutes (top), 30 minutes (middle), and 90 minutes (bottom) 
after LPS administration. Western blots are representing two animals out of each group 
consisting of five animals. Western blot membranes for total amounts of p38 MAPK (totp38) 
are shown to ensure equal protein loading. Western blot analysis has been performed in 
duplicate. 
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3.3.3 INFLUENCE OF ANP ON THE REGULATION OF NF-κB AND IκBα 
The transcription factor NF-κB is one of the most important “players” within the LPS signaling 
pathway ([3] Akira, 2004). Following activation, NF-κB translocates into the nucleus, binds to 
its corresponding DNA-sequence, and finally promotes expression of several cytokines 
(Figure 3:12). Therefore, ANP mediated influences on NF-κB binding activity might be 
responsible for final differences in TNF-α expression. 
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Figure 3:12 The NF-κB signaling cascade. After IκBα phosphorylation subsequent degradation occurs of 
this protein. The transcription factor NF-κB, consisting of two subunits, translocates into the 
nucleus, and finally promotes expression of several cytokines, such as TNF-α. 
3.3.3.1 REGULATION OF THE TRANSCRIPTION FACTOR NF-κB 
Changes in TNF-α plasma levels already occur 90 minutes after LPS injection. Thus, we 
focused on the early effects on NF-κB binding activity in the nucleus caused by ANP 
preconditioning in the model of LPS-induced sepsis. As demonstrated in Figure 3:13, LPS 
treatment significantly increases NF-κB binding activity in whole liver homogenates. This 
characteristic effect has previously been described, in the model of LPS-induced sepsis ([3] 
Akira, 2004). Neither NF-κB binding activity in tissue of NaCl (control) treated animals has 
been detectable, nor does ANP injection seem to have any influence on binding activity of 
the transcription factor. Preconditioning with ANP in LPS-induced septic shock provoked a 
decrease in NF-κB binding activity as soon as 15 minutes after LPS injection. This effect is 
still detectable 30 minutes after LPS-induced endotoxemia. 
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Figure 3:13 ANP pretreatment reduces NF-κB binding activity in whole liver homogenates after LPS-
induced septic shock. Animals were preconditioned with ANP (ANP/LPS group) 15 minutes 
previous to LPS (LPS group) injection. Mice, only receiving NaCl (control group) or ANP (ANP 
group) were used to identify an impact of these substances on NF-κB binding activity.  Organ 
samples were obtained 15 (top) and 30 (bottom) minutes after LPS injection. Whole liver 
homogenates were analyzed by electro-mobility-shift assay. Pictures are representing three 
animals out of each group consisting of five animals.  EMSA has been performed in duplicate. 
3.3.3.2 REGULATION OF THE NF-κB INHIBITORY FACTOR IκBα 
Following determination of NF-κB activation, we were interested in upstream mechanisms 
leading to ANP mediated inhibition of NF-κB binding activity. IκBα, the inhibitory factor of  
NF-κB prevents its translocation from the cytosol into the nucleus, and therefore inhibits 
transcription of respective genes. Following phosphorylation by its corresponding kinase IKK, 
IκBα is subsequently ubiquitinylated and degraded within the proteasome. As demonstrated 
in Figure 3:14, corresponding to NF-κB binding activity, we observed increased IκBα 
phosphorylation 15 and 30 minutes after LPS injection. Decreased levels of total amounts of 
IκBα have been detected 30 minutes after LPS injection. 
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This effect points to an increased degradation of the NF-κB inhibitory factor. ANP 
preconditioning causes strong decreases in LPS-induced IκBα phosphorylation. This finally 
results in a higher content of the inhibitory factor, most likely due to minor degradation of 
IκBα 30 minutes after LPS injection. 
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Figure 3:14 ANP pretreatment reduces IκBα phosphorylation, resulting in minor degradation of IκBα 
protein in whole liver homogenates after LPS-induced septic shock. Animals were 
preconditioned with ANP (ANP/LPS group) 15 minutes previous to LPS (LPS group) injection. 
Mice, only receiving NaCl (control group) or ANP (ANP group) were used to identify an impact 
of these substances on IκBα phosphorylation and degradation.  Organ samples were obtained 
15 (top) and 30 (bottom) minutes after LPS injection. Whole liver homogenates were analyzed 
by western blot and IκBα has been determined using specific antibodies, detecting 
phosphorylated (pIκBα) and total amounts of IκBα (totIκBα). Blots are representing two 
animals out of each group consisting of five animals.  Western blot has been performed in 
duplicate. 
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3.3.4 CELL DEPENDENT REGULATION OF TRANSCRIPTIONAL ACTIVITY 
Effects on the nuclear factor-κB and its inhibitory factor IκBα have always been seen in 
whole organ homogenates. In order to further investigate signaling cascades involved in ANP 
mediated TNF-α reduction in septic-shock, cell dependent investigations had to be done. 
Thus, we were interested in the cell type responsible for changes in NF-κB activity, which 
might finally contribute to decreased TNF-α mRNA expression in ANP preconditioned 
endotoxemic liver samples. 
3.3.4.1 p65 LOCATION IN LIVER TISSUE 
NF-κB, a known heterodimer, mainly consists of the p65 and the p50 subunits. In order to 
determine the cell type involved in changes within NF-κB binding activity, we focused on the 
distribution of the NF-κB subunit p65. Therefore, “NF-κB” translocation into the nucleus has 
been investigated by staining of p65 in frozen slices of liver tissue. Parallel, resident liver 
macrophages, also denoted as Kupffer cells, were stained to differentiate between Kupffer 
cells and hepatocytes. Images were obtained by confocal-microscopy. As frequently 
described ([16] Bilzer, 2005), we expected Kupffer cells to be responsible for changes in  
NF-κB binding activity. Surprisingly, both Kupffer cells (Figure 3:15-a) as well as hepatocytes 
(Figure 3:15-b) show a significant increase in p65 translocation into the nucleus, seen 30 
minutes after LPS injection.  Interestingly, ANP preconditioning reduces translocation of p65 
in Kupffer cells as well as in hepatocytes, shown by decreased p65 appearance in the 
nucleus of both cell types (Figure 3:15). 
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Figure 3:15 ANP prevents translocation of the NF-κB subunit p65 into the nucleus. Animals were 
preconditioned with ANP (ANP/LPS group) 15 minutes previous to LPS (LPS group) injection. 
Mice, only receiving NaCl (control group) or ANP (ANP group) were used to identify an impact 
of these substances on p65 translocation.  Organ samples were obtained 15 (top) and 30 
(bottom) minutes after LPS injection. Liver slices were stained with specific conjugated 
antibodies to determine p65 location by microscopy; blue: nucleus of Kupffer cells (a) and 
hepatocytes (b); green: macrophages/Kupffer cells (a); red: NF-κB subunit p65. 
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3.4 HEPATOCYTES 
The liver is made up of different cell populations. The 
most abundant cell type by mass and by number are 
the hepatocytes. Surprisingly, not only Kupffer cells 
but also hepatocytes showed elevated p65 
translocation into the nucleus after LPS injection. This 
effect is supposed to be associated with NF-κB 
activity. ANP preconditioning prevents p65 
translocation into the nucleus in both cell types, pointing to an involvement of hepatocytes in 
ANP mediated protection from LPS-induced septic shock. Much research has been done to 
investigate the response of Kupffer cells to bacterial products, such as LPS. But only little is 
known about the LPS response of the livers major cell type, the hepatocytes. 
3.4.1 INFLUENCE OF ANP ON THE REGULATION OF NF-κB AND IκBα 
The regulation of NF-κB is tightly controlled. Activation of the transcription factor NF-κB is 
mediated through phosphorylation and degradation of its inhibitory factor IκBα. We 
investigated the nuclear factor-κB binding activity, and phosphorylation as well as 
degradation of its inhibitory factor IκBα in whole liver homogenates (3.3). Now, we were 
interested in the microbial response of primary isolated hepatocytes. Effects on TNF-α serum 
levels have been seen to peak 90 minutes after LPS-induced septic shock in mice (3.1). As 
previously determined, changes in NF-κB binding activity have already been detectable 15 
minutes after LPS injection, in whole liver homogenates (3.3.3.1). Therefore, we focused on 
NF-κB binding activity and corresponding changes in IκBα phosphorylation and degradation, 
30 minutes after LPS stimulation of isolated hepatocytes. Cells were used for experiments 24 
hours after isolation. In primary isolated hepatocytes, we investigated NF-κB binding activity 
and IκBα phosphorylation and degradation. Hence, we were conscious about receptor and 
surface molecule reduction during the process of hepatocyte isolation. Complete ANP 
receptor recovery has previously been described in hepatocytes 24 hours after isolation 
([104] Kulhanek-Heinze, 2004). But, to exclude an influence by cells lacking receptor and 
surface molecules, hepatocytes have additionally been cultivated for 48 hours and NF-κB 
binding activity has comparatively been determined. 
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3.4.1.1 REGULATION OF NF-κB IN 24 HOURS CULTIVATED HEPATOCYTES 
Transcription factor binding activity has hardly been detectable in NaCl and ANP treated cells 
30 minutes after stimulation. Interestingly, as seen in Figure 3:16, 30 minutes of LPS 
stimulation does not cause any changes in NF-κB binding activity. Stimulation with TNF-α 
alone as well the combination of LPS and TNF-α significantly increases binding activity of the 
nuclear factor to the same extends. Interestingly, neither an impact on NF-κB binding activity 
by ANP preconditioning in TNF-α nor in LPS plus TNF-α stimulated isolated hepatocytes has 
been detectable. 
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Figure 3:16 ANP pretreatment does not show any changes on TNF-α and LPS+TNF-α induced NF-κB 
binding activity in 24 hours cultivated hepatocytes. Cells were preconditioned with ANP 
(ANP/LPS, ANP/TNF-α and ANP/LPS+TNF-α group) 15 minutes previous to LPS and/or  
TNF-α  stimulation (LPS, TNF-α and LPS+TNF-α group). Cells receiving NaCl (control group) 
or ANP (ANP group) were used to identify an impact of these substances on NF-κB binding 
activity.  Cells were harvested 30 minutes after LPS and/or TNF-α administration. NF-κB 
binding activity was determined by EMSA. Illustrations show one representative experiment 
out of three performed experiments. Positive control (Pc) and negative control (Nc) were 
performed as described under 2.5.4.1. 
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3.4.1.2 REGULATION OF IκBα IN 24 HOURS CULTIVATED HEPATOCYTES 
Following phosphorylation by its corresponding kinase, IκBα is subsequently ubiquitinylated 
and degraded within the proteasome. After determining NF-κB binding activity, we were 
interested in changes in IκBα degradation. Corresponding to NF-κB binding activity observed 
30 minutes after LPS administration, we did not detected any decrease in total amounts of 
total IκBα protein 30 minutes after LPS stimulation. This effect does not point to an increased 
degradation of the NF-κB inhibitory factor in LPS stimulated hepatocytes. Conclusively, 
solely LPS treatment did not only display unaffected NF-κB binding activity but also 
unaffected amounts of total IκBα protein in the cytosol. 
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Figure 3:17 LPS stimulation does not show any decrease in total amounts of IκBα in 24 hours cultivated 
primary hepatocytes. Cells were preconditioned with ANP (ANP/LPS group) 15 minutes 
previous to LPS and/or TNF-α  (LPS, TNF-α and LPS+TNF-α group) stimulation. Cells, only 
receiving NaCl (control group) or ANP (ANP group) were used to identify an impact of these 
substances on total amounts of IκBα.  Cells were harvested 30 minutes after LPS and/or  
TNF-α administration. Cell extracts were analyzed by western blot. Blots are showing one 
representative experiment out of three performed experiments. 
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3.4.1.3 REGULATION OF NF-κB IN 48 HOURS CULTIVATED HEPATOCYTES 
Above mentioned (3.4.1.1), NF-κB binding activity has hardly been detectable in NaCl and 
ANP treated hepatocytes. As displayed in Figure 3:18, 48 hours of cultivation after isolation, 
had no impact on NF-κB activation 30 minutes after LPS stimulation. TNF-α stimulation 
significantly increases transcription factor NF-κB binding activity in nuclear extracts of 
hepatocytes. However, as seen before, there have not been any detectable changes in  
NF-κB binding activity, by ANP preconditioning 30 minutes after TNF-α stimulation. Though, 
48 hours cultivated hepatocytes seem to be more constant, but don’t show any changes, 
within their recognition pattern in 30 minutes of LPS or TNF-α treatment. 
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Figure 3:18 ANP pretreatment does not show any changes in TNF-α induced NF-κB binding activity in 48 
hours cultivated hepatocytes. Cells were preconditioned with ANP (ANP/LPS, ANP/TNF-α 
group) 15 minutes previous to LPS or TNF-α  (LPS and TNF-α group) stimulation. Cells, only 
receiving NaCl (control group) or ANP (ANP group) were used for control experiments. Cells 
were harvested 30 minutes after LPS or TNF-α administration. NF-κB binding activity was 
determined by EMSA. Graphs are representing the evaluation of three performed 
experiments. Illustration shows one representative experiment. EMSA for each experiment 
has been performed in duplicate. 
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3.5 BLOOD 
In our LPS-induced septic shock model we observed reduced TNF-α 
plasma levels in ANP preconditioned mice, peaking 90 minutes after 
LPS administration (3.1). For this reason, we investigated contributions 
of heart, spleen and liver to decreased TNF-α expression. Hereon, we 
analyzed signaling pathways, consequently leading to previous 
determined TNF-α mRNA expression in murine liver samples. Interestingly, there is still one 
major “organ system” connecting all just mentioned organs. Thus, we were mainly interested 
how ANP preconditioning influences LPS-induced TNF-α expression in murine leukocytes ex 
vivo. In order to verify effects primarily determined in murine blood samples, we further 
investigated TNF-α expression in human blood leukocytes, in particular monocytes and 
granulocytes. 
3.5.1 MURINE BLOOD LEUKOCYTES 
The determination of whole TNF-α protein contents including the permeabilization of samples 
receiving BD golgi-plug has been accomplished according to 2.3.3 descriptions. Analysis of 
TNF-α expression exclusively on the cell surface 
was performed by allowing leukocytes to release 
TNF-α upon stimulation. As displayed in  
Figure 3:19, following FACS measurement, cells 
have been gated and TNF-α expression has 
been analyzed in murine leukocytes. The results 
shown in Figure 3:20  demonstrate that ANP 
administration does not seem to have any impact 
neither on cell surface nor on total amounts of 
TNF-α expression compared to control 
experiments. 
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Figure 3:19 Dot plot of murine blood leukocytes gained by FACS analysis. Gated cell population 
represents murine leukocytes, respectively monocytes (a) and granulocytes (b) (neutrophils). 
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Interestingly, 90 minutes of LPS stimulation increases total amount of TNF-α, which are not 
reflected in TNF-α contents expressed on cell surface. ANP preconditioning slightly 
decreases total amounts of TNF-α in murine leukocytes. Additionally, preconditioning with 
ANP in 90 minutes LPS stimulated blood samples almost completely inhibits expression of 
TNF-α on leukocyte cell surface. These findings point to an involvement of ANP in LPS-
induced TNF-α expression in murine blood cells. 
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Figure 3:20 ANP pretreatment of 90 minutes LPS stimulated whole blood samples shows slight changes 
on TNF-α expression in murine leukocytes.  Whole blood samples were preconditioned with 
ANP (ANP and ANP/LPS group) 15 minutes previous to LPS administration (LPS group). 
Samples, only receiving NaCl (control group) were used for control experiments. Following 90 
minutes of stimulation cells were immediately fixed and TNF-α amounts were analyzed using 
antibody staining and FACS analysis. Graphs are representing TNF-α expression determined 
on cell surface (left) and total TNF-α contents (right) in murine blood leukocytes. Analyses are 
representing the evaluation of ten performed experiments. 
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3.5.2 HUMAN BLOOD LEUKOCYTES 
Investigating influences of ANP in LPS treated murine blood samples displayed one major 
drawback, the amount gained from each animal. In order to investigate influences of ANP on 
leukocytes on the one hand and to determine parallels between murine and human blood 
samples on the other hand, we analyzed different cell populations of human blood 
leukocytes. Human blood samples were used for TNF-α mRNA determination and FACS 
analysis. These samples were taken from healthy male volunteers and subsequently 
stimulated with different ANP and LPS concentrations. Leukocytes were treated with 25nM 
and 1µM ANP, and 100ng/ml, 1µg/ml and 10µg/ml LPS, respectively. As demonstrated in, for 
FACS analysis, two leukocyte populations, in detail monocytes (a) and neutrophils (b) were 
gated and analyzed separately. 
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Figure 3:21 Dot plot of human blood leukocytes gained by FACS analysis. Different cell populations are 
representing monocytes (a) and neutrophils (granulocytes) (b). 
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3.5.2.1 INFLUENCE OF ANP ON LPS-INDUCED TNF-α mRNA EXPRESSION 
Since the previous results determined in murine blood samples indicate changes in TNF-α 
expression on the cell surface, the question arises, which mechanism contributes to this 
effect? In order to investigate, if the determined changes result from divergences of 
transcriptional activity, TNF-α mRNA content has been evaluated using real time RT-PCR 
analysis. After 30 minutes of LPS administration, significant increases in TNF-α mRNA 
expression have been detected compared to control and ANP treated blood samples. 
However, analyzed mRNA contents in ANP preconditioned human blood leukocytes did not 
display any differences compared to non-pretreated LPS stimulated blood samples. 
This indicates that previously determined changes in TNF-α cell surface expression in mouse 
derived blood samples are most likely not a result of transcriptional regulation, but rather 
underlie posttranscriptional processes. 
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Figure 3:22 ANP preconditioning of whole blood samples does not show any changes in LPS-induced 
TNF-α mRNA expression. Whole blood samples were preconditioned with ANP 15 minutes 
(ANP and ANP/LPS group) previous to LPS injection (LPS and ANP/LPS group). Samples, 
only receiving NaCl (control group) or (ANP group) were used to identify an impact of these 
substances on TNF-α mRNA expression.  Leukocyte mRNA was isolated 30 minutes after 
LPS stimulation. Samples were analyzed by real time RT-PCR. The graph represents  
real time RT-PCR analysis from four experiments. 
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3.5.2.2 CHANGES IN TNF-α EXPRESSION ON CELL SURFACE IN LEUKOCYTES 
As demonstrated in Figure 3:23, LPS stimulation of whole human blood samples influences 
the TNF-α expression on cell surface in human blood neutrophils. Graphs (control and LPS) 
are demonstrating one representative example of two different stimulations, respectively 
NaCl (control) and LPS (100ng/ml). Thereby, following 30 minutes of LPS stimulation, TNF-α 
protein accumulates on the cell-surface of human blood derived neutrophils compared to 
NaCl treated blood samples. This effect is clearly detectable by analyzing the FL1-H 
histogram plot overlay of both stimulations. This overlay displays a slight sideward shift of the 
histogram plot representing LPS treated neutrophils. 
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Figure 3:23 LPS stimulation influences TNF-α  expression on cell surface in human blood neutrophils. 
Granulocytes of NaCl (control) or LPS treated blood samples were immediately fixed 30 
minutes after LPS (100ng/ml) administration. TNF-α amounts on cell surface were determined 
using antibody staining and FACS analysis. Histogram plots demonstrate one representative 
example out of all performed experiments. 
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Figure 3:24 and Figure 3:25 show that LPS stimulation of whole blood samples significantly 
influences TNF-α appearance on leukocyte cell surface. Interestingly ascending LPS 
concentrations from 100ng/ml to 10µg/ml finally lead to complete removal of cell surface 
TNF-α protein in neutrophils as well as in monocytes. ANP preconditioning with different 
concentrations, diversely influences TNF-α contents via further reduction of detectable  
TNF-α amount on cell surface. This additive reduction caused by ANP pretreatment has 
been detectable in 100ng/ml and 1µg/ml LPS stimulated blood neutrophils and monocytes. 
co
nt
ro
l
AN
P2
5n
M
AN
P1
µM
LP
S1
00
ng
/m
l
AN
P2
5n
M
+L
PS
10
0n
g/
m
l
AN
P
1µ
M
+L
PS
10
0n
g/
m
l
LP
S1
µg
/m
l
A
N
P
25
nM
+L
P
S
1µ
g/
m
l
AN
P1
µM
+L
PS
1µ
g/
m
l
LP
S
10
µg
/m
l
AN
P
25
nM
+L
P
S
10
µg
/m
l
AN
P1
µM
+L
PS
10
 µ
g/
m
l0
50
100
150
200
250
TN
F-
α
 o
n 
ce
ll-
su
rfa
ce
 in
 %
*
NaCl X XX X X X
ANP 25nM X X XX
ANP 1µM X X XX
LPS 100ng/ml X XX
LPS 1µg/ml X X X
LPS 10µg/ml X X X
neutrophils
co
nt
ro
l
AN
P2
5n
M
AN
P1
µM
LP
S1
00
ng
/m
l
AN
P2
5n
M
+L
PS
10
0n
g/
m
l
AN
P
1µ
M
+L
PS
10
0n
g/
m
l
LP
S1
µg
/m
l
A
N
P
25
nM
+L
P
S
1µ
g/
m
l
AN
P1
µM
+L
PS
1µ
g/
m
l
LP
S
10
µg
/m
l
AN
P
25
nM
+L
P
S
10
µg
/m
l
AN
P1
µM
+L
PS
10
 µ
g/
m
l
TN
F-
α
 o
n 
ce
ll-
su
rfa
ce
 in
 %
 
Figure 3:24 ANP pretreatment of LPS stimulated whole human blood shows slight changes on TNF-α 
expression on cell surface of human blood granulocytes. Whole human blood samples were 
preconditioned with ANP (ANP and ANP/LPS group) 15 minutes previous to LPS (LPS group) 
administration. Cells, only receiving NaCl (control group) were used for control experiments. 
Following 30 minutes of LPS stimulation, cells were immediately fixed and TNF-α amounts on 
cell surface were determined using antibody staining and FACS analysis. TNF-α cell-surface 
expression is calculated in percent, assuming 100% for the solely ANP (1µM) stimulated 
group. Graphs are representing the evaluation of four performed experiments. Each 
experiment has been performed in duplicate. 
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Surprisingly, 10µg/ml LPS treated blood samples preconditioned with ANP do not display any 
additional effects in TNF-α reduction on cell surface. Moreover, high dose LPS treated blood 
samples, irrespective of ANP preconditioning, completely remove TNF-α from the cell 
surface. Leukocytes treated with 100ng/ml LPS, which represents the lowest applied LPS 
concentration, benefit most of all from ANP preconditioning in a dose dependent manner. 
Following ANP preconditioning, reduced TNF-α cell surface expression is not only detectable 
in neutrophils but also in monocytes. Finally, we can reason that human derived blood 
samples mainly differ from murine blood samples regarding its more sensitive inflammatory 
response. 
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Figure 3:25 ANP pretreatment of LPS stimulated whole human blood shows slight changes on TNF-α 
protein expression on cell surface of human blood monocytes. Whole human blood samples 
were preconditioned with ANP (ANP and ANP/LPS group) 15 minutes previous to LPS (LPS 
group) administration. Cells, only receiving NaCl (control group) were used for control 
experiments. Cells were immediately fixed 30 minutes after LPS administration. TNF-α 
amounts on cell surface were determined using antibody staining and FACS analysis. TNF-α 
cell-surface expression is calculate in percent, assuming 100% for the solely ANP (1µM) 
stimulated group. Graphs are representing the evaluation of four performed experiments. 
Each experiment has been performed in duplicate. 
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4.1 TNF-α mRNA EXPRESSION 
The kinetics of cytokine release into the circulation has frequently been studied in 
experimental models of infection and inflammation. In these models tumor necrosis factor-α 
(TNF-α) has always been the very first cytokine appearing in the blood stream ([42] Damas, 
1997c; [172] Tom van der Poll, 1999). Interestingly, infusion of low doses of LPS into healthy 
human volunteers resulted in sepsis like symptoms and rapid release of TNF-α into the 
circulation, peaking 90 minutes after endotoxin administration ([126] Martich, 1993; [133] 
Michie, 1988). Therefore, TNF-α can be considered to be one of the most prominent 
cytokines released during bacterial infection and sepsis ([41] Damas, 1997b). Besides its 
intensively studied proinflammatory functions, TNF-α still represents one of the exceedingly 
discussed proteins associated with inflammation and septic-shock. On the one hand, 
increased TNF-α levels have frequently been associated with enhanced mortality in septic 
shock in humans ([36] Collighan, 2004a). The reduction of TNF-α plasma levels contributes 
to improved survival in a murine LPS-induced shock model ([60] Gorgen, 1992).  On the 
other hand, with respect to efficiency of anti-TNF-α treatment, several studies revealed only 
little benefit on the outcome of sepsis and septic shock. Within these randomized trials, 
neither anti-TNF-α antibodies nor soluble TNF-α receptors have been demonstrated to 
significantly improve survival in septic patients ([152] Reinhart, 2001). 
Besides all controversy, it has been shown that the peak concentrations of TNF-α, 
determined in plasma, were initially significantly different between patients suffering from 
severe sepsis and patients being affected by septic shock. Exclusively, patients with rapid 
onset of septic shock demonstrated high but transient TNF-α concentrations ([37] Collighan, 
2004b; [40] Damas, 1997a). Therefore, the rapid and early intervention might be very 
beneficial for the outcome of sepsis. In our model of LPS-induced sepsis, we demonstrated 
that ANP preconditioning rescued mice from septic shock by 80%. Further on, the survival 
was accompanied by significantly reduced TNF-α levels determined in plasma 90 minutes 
after LPS injection ([91] Keller, 2005a). Hereon, in a separate group of animals, we analyzed 
various selected organs, heart, spleen and liver, for determination of TNF-α gene expression 
following ANP preconditioning in a murine septic shock model. 
- Atrial cardiocytes in the heart of mammals produce the polypeptide hormone ANP ([129] 
McGrath, 2005). Interestingly, recent findings indicate that patients suffering from septic 
shock are characterized by significantly elevated ANP plasma levels ([191] Witthaut, 
2003). 
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 Notably, early studies in 1988 already recognized enhanced ANP levels in endotoxin 
infected sheep. Moreover, at that time it has primarily been concluded that ANP should be 
considered as a potential mediator during the pathogenesis of sepsis ([121] Lubbesmeyer, 
1988). 
- The spleen is one of the most important organs in the innate immune system for 
antimicrobial reactivity. Its unique structure enables it to an efficient remove of blood-borne 
microorganisms and their products, as LPS. Patients without spleens have an increased 
risk of infection ([130] Mebius, 2005). Additionally, various studies have shown that 
spleenectomy significantly influences TNF-α expression of different populations of 
macrophages, such as peripheral blood mononuclear cells and resident liver macrophages 
([164] Shih-Ching, 2004). 
- Besides the spleen, being the first organ, confronted with microbial products absorbed by 
the gastrointestinal tract, the liver is mainly involved in host-defense mechanisms. In 
particular, Kupffer cells are activated by bacterial stimuli, as LPS, and subsequently 
produce various cytokines, foremost TNF-α ([8] Ashare, 2006). Interestingly, Kupffer cells, 
derived from mice that survive LPS-induced septic shock have been demonstrated to 
significantly produce less TNF-α upon LPS stimulation compared to solely LPS-treated 
mice ([60] Gorgen, 1992). 
Conclusively, these three organs most likely seem to be involved in ANP mediated protective 
effects during LPS-induced sepsis. Examination of TNF-α mRNA expression exhibits 
different effects in heart, liver and spleen. Following ANP preconditioning spleen and liver 
showed significantly decreased LPS-induced TNF-α mRNA expression. This result does not 
appear in the heart, where gene expression has not been affected by ANP pretreatment. 
This shown effect indicates that protective mechanisms, leading to TNF-α reduction seem to 
be linked to immunoreactive organs, comprising a great value of resident tissue 
macrophages. According to our investigations, we can ascertain that following ANP 
preconditioning, spleen and liver might contribute to decreased LPS-induced TNF-α protein 
levels determined in plasma. As mentioned above, plasma levels of ANP and its precursor 
protein pro-ANP have been demonstrated to be highly increased in septic patients. 
Therefore, endogenous ANP is supposed to be an important regulatory mediator in 
inflammation and sepsis ([191] Witthaut, 2003).  Interestingly, we can specify that the heart, 
which represents the main compartment liberating ANP into the circulation, significantly 
contributes to TNF-α mRNA expression in LPS-induced sepsis. However, this organ does 
not display any changes in TNF-α mRNA expression in ANP preconditioned organs in LPS-
induced septic shock. 
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4.2 THE LIVER 
Approximately 50% of septic patients develop evidence of organ injury, including liver 
dysfunction, which is an important determinant of survival ([35] Cohen, 2002). As previously 
described, the liver clears the blood of bacterial endotoxins and subsequently produces 
cytokines in response to these stimuli during the course of infection (see chapter 1.4.1). In 
addition, it has been shown, that impaired clearance of injected particulates from the blood 
stream by the liver is associated with subsequent increased severity of infection ([8] Ashare, 
2006; [154] Rimola, 1984). Consequently, the liver seems to play a major role in mediating 
inflammatory diseases and hepatic dysfunction that may greatly influence the outcome of 
sepsis. In the murine model of LPS-induced sepsis, we were able to detect a great impact of 
ANP preconditioning on TNF-α mRNA expression in whole liver homogenates. Therefore, we 
decided to further investigate signaling mechanisms, leading to or arising from reduced  
TNF-α mRNA expression in murine liver tissue. 
4.2.1 HISTOLOGICAL CHANGES IN LIVER TISSUE 
For the purpose of identification of early histological changes, we focused on apoptosis as 
well as on leukocyte infiltration in liver tissue derived from endotoxemic mice. 
Different studies indicted a major impact of immigrated leukocytes in nonspecific host 
defenses to microbial infections within the liver. They postulate that the majority of pathogens 
is subsequently killed by immigrating leukocytes mobilized rapidly to the liver in response to 
infection. Additionally, immunohistochemical analysis of liver sections revealed the massive 
immigration of leukocytes two hours after infection ([62] Gregory, 1996; [61] Gregory, 2002a; 
[63] Gregory, 2002b). Interestingly, following 90 minutes of LPS treatment, we did not detect 
any immunohistochemical changes, respectively leukocyte infiltration as far as to this 
moment. Conclusively, we firstly presume that ANP mediated protective effects determined 
in the liver do not arise from infiltrated leukocytes but rather originate from liver cells. 
Secondary, there can not be ascertained any pathologic apoptotic cell death of hepatocytes 
focusing on 90 minutes after LPS administration.  This time point is supposedly too early to 
detect any apoptotic cell death. Indeed, in regard to apoptosis, our investigations are in great 
consistence with recent findings, which propose that hepatocyte apoptosis only seems to be 
a minor phenomenon in endotoxic shock in mice. Furthermore, liver failure due to high doses 
of endotoxins was mainly characterized by single cell necrosis at later time points ([22] 
Bohlinger, 1996; [186] Wang, 1995). 
4 Discussion   - 84 -    
4.2.2 THE NF-κB AND IκBα SIGNALING PATHWAY IN THE WHOLE LIVER 
Many of the LPS caused effects are mediated through the activation of the transcription 
factor NF-κB. To date, over 200 genes are known to be regulated by NF-κB ([2] Aggarwal, 
2003). Amongst these genes, NF-κB is mainly involved in modulating the expression of TNF-
α ([68] Hanada, 2002). It is known, that LPS administration subsequently leads to NF-κB 
activation resulting in the production of TNF-α by resident liver macrophages, also referred to 
as Kupffer cells ([45] Decker, 1998). Conclusively, the inhibition of NF-κB transcriptional-
activity in the liver was regarded as a potential therapeutic target to prevent NF-κB mediated 
liver injury. Unfortunately, the NF-κB signaling pathway appears to be central to innate 
immunity and mediates not only cellular responses to LPS but also to TNF-α. Production of 
TNF-α is rapidly induced by LPS, and consequently contributes to NF-κB activation by 
binding to its TNFR-1 in the liver. Therefore, TNF-α acts to amplify inflammatory signaling 
([102] Koay, 2002). Additionally, the possibility that NF-κB activation in hepatocytes is 
protective following liver injury points to even more complexity of events following global 
activation of NF-κB in all hepatic cell types. 
Besides all complexity, recent studies indicate that NF-κB binding activity is significantly 
diminished in liver, following LPS administration in TNFR-1 knock out mice ([102] Koay, 
2002; [142] Nowak, 2000). Interestingly, cell-associated TNF-α was shown to contribute 
small effects to hepatic injury. Whereas, secreted TNF-α, also denoted as soluble TNF-α 
(solTNF-α) was proven to mainly mediate mechanisms leading to hepatic dysfunction ([142] 
Nowak, 2000). Moreover, various studies demonstrate that blocking the TNF-α processing 
with matrix metalloproteinase inhibitors protects against endotoxin induced liver injury and 
lethality in mice ([56] Gearing, 1995; [137] Mohler, 1994). Together, all these findings 
suggest that endotoxin induced NF-κB activation at least partially requires soluble TNF-α and 
its corresponding receptor TNFR-1 in liver tissue. 
We analyzed the endotoxin-induced binding activity and translocation of the transcription 
factor NF-κB. In the present study our investigations of NF-κB binding activity in murine liver 
homogenates clearly prove a significant increase in NF-κB-DNA binding as soon as 15 
minutes after LPS administration. Interestingly, ANP preconditioning compensates this 
inflammatory effect by causing a reduction of LPS provoked NF-κB-DNA binding. 
Additionally, determination of NF-κB activation in regard to cell-type dependency exhibits 
most interesting effects on p65 translocation.  Dimerization of the p50 and p65  
NF-κB subunits is essential for transcription factor activation. 
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Interestingly, the p50 subunit lacks this transactivating domain, which enables NF-κB to 
activate gene transcription ([20] Blackwell, 1997). However, the p65 subunit seems to be 
crucial for NF-κB transcriptional activity ([179] Viatour, 2005). Following activation, NF-κB 
translocates from the cytosol into the nucleus. Hence, to determine cell type specific NF-κB 
activation, we focused on the NF-κB subunit p65 in antibody stained liver slices. Surprisingly, 
p65 translocation not only occurred as primarily suggested in Kupffer cells but has also been 
greatly detectable in hepatocytes. Furthermore, in both cell types, ANP preconditioning 
diminished LPS-induced p65 translocation into the nucleus. These findings reveal the close 
interaction of Kupffer cells and hepatocytes in LPS-induced hepatic inflammatory disorders. 
Regulation of NF-κB transcriptional activity is facilitated by reversible binding of IκBα to the 
NF-κB complex. Nevertheless, concepts about NF-κB separation, its translocation into the 
nucleus and mechanism finally leading to activation have recently been discussed 
intensively. On the one hand, various studies indicate the dependency of NF-κB activation by 
phosphorylation and degradation of its inhibitory protein IκBα ([86] Karin, 2000). To date, this 
theory seems to be the most privileged NF-κB signaling pathway. On the other hand, it has 
been postulated that NF-κB activation primarily depends on IκBα degradation without 
requirement of former phosphorylation ([72] Henkel, 1993; [86] Karin, 2000). Independent of 
all confusions, it has been shown that LPS-induced increase in NF-κB mediated luciferase 
activity was dependent on the intact IκBα protein by selective expression of an IκBα 
dominant negative form (IκBα-DN) in the liver. Blackwell and colleagues demonstrated that 
they were able to completely suppress LPS-induced luciferase expression in IκBα-DN 
organs ([21] Blackwell, 2000). For this reason, we were interested in signaling pathways 
leading to decreased LPS-induced NF-κB binding activity in ANP preconditioned livers. 
Therefore, we focused on changes in IκBα phosphorylation and degradation. 
As seen in our experiments a strong phosphorylation of the NF-κB inhibitory protein IκBα 
occurs as soon as 15 minutes after LPS injection. Besides, LPS-induced increased 
phosphorylation, decreased levels of total IκBα protein can be determined 30 minutes after 
LPS administration. This clearly points to an ensuing degradation of IκBα. To agree with 
determined influences on NF-κB binding activity, LPS-induced phosphorylation of IκBα has 
been reduced in ANP pretreated liver homogenates. Furthermore, reduced phosphorylation 
in ANP preconditioned organs is accompanied by exceeding IκBα protein levels compared to 
organs derived from septic mice, leading to assumption of decreased IκBα degradation. 
Altogether, we suppose that the ANP-mediated diminished NF-κB binding activity in 
endotoxemic livers is evoked via the cardinally described NF-κB and IκBα signaling pathway. 
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In brief, ANP inhibits the phosphorylation and degradation of IκBα resulting in the prevention 
of NF-κB transcriptional activity in whole liver homogenates. This effect might be a result of 
direct ANP interference within the LPS-induced NF-κB activating pathways (Figure 4:1). 
Furthermore, our findings indicate various parallels to a body of pharmacological data, 
describing the termination of primarily endotoxin-induced TNF-α signaling protecting against 
further NF-κB activation, and consecutively reducing liver inflammation and organ failure. 
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Figure 4:1 Influences of ANP on the NF-κB & IκBα signaling pathway in the liver. 
 
4.2.2.1 INFLUENCES OF ANP ON LPS STIMULATED HEPATOCYTES 
After investigating NF-κB subunit p65 translocation into the nucleus, we have been 
astonished, detecting p65 not only in Kupffer cells but also in the nucleus of hepatocytes as 
soon as 30 minutes after LPS injection. Superiorly, in both cell types, ANP preconditioning 
markedly reduced LPS-induced p65 translocation. In the intact liver, hepatocytes are always 
in direct contact to Kupffer cells. Therefore, the present experiments were firstly designed to 
assess whether direct contact between hepatocytes and Kupffer cells is of influence for  
LPS-induced augmented NF-κB binding activity. 
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Secondly, we were interested, if previously determined ANP mediated reduction of LPS-
induced NF-κB binding activity, will still be detectable in isolated hepatocytes. 
Besides LPS-induced Kupffer cell activation, the direct responsiveness of hepatocytes to 
LPS stimulation has been widely discussed. Interestingly, hepatocytes express the whole 
molecular necessities to respond to LPS, such as TLR-4, CD14 and MyD88 ([115] Li, 2002b; 
[181] Vodovotz, 2001). Based on this knowledge, hepatocytes have been demonstrated to 
directly respond to LPS by activation of NF-κB ([119] Liu, 2002). Conclusively, it has been 
suggested that hepatocytes respond to LPS in a manner at least qualitatively similar to 
Kupffer cells ([119] Liu, 2002). However, in contrast to Kupffer cells, where NF-κB activation 
is responsible for cytokine production, NF-κB activation in hepatocytes is basically supposed 
to result in induction of several acute phase proteins and iNOS ([109] Laskin, 1995; [138] 
Monshouwer, 2003; [156] Saad, 1995). However, besides the direct activation of hepatocytes 
by LPS, hepatocytes are also activated by proinflammatory cytokines released by LPS 
activated Kupffer cells. For this reason, hepatocytes exhibit several cytokine receptors, for 
instance TNFR-1. The activation of this receptor does not only activate NF-κB but also plays 
a central role in the pathogenesis of LPS-induced liver injury. 
For this reason, several studies have focused on the importance of direct contact between 
hepatocytes and Kupffer cells during the hepatic inflammatory response. In these 
experiments the LPS-induced inflammatory response of hepatocytes has been compared to 
co-cultures, comprising hepatocytes and Kupffer cell. Interestingly, these studies revealed 
that only co-cultures exhibit a great production of TNF-α, whereas TNF-α release was mainly 
accomplished by Kupffer cells ([74] Hoebe, 2001). Today, it is commonly accepted that 
Kupffer cells are among the first cells that respond to LPS ([52] Freudenberg, 1982). Cellular 
communication between Kupffer cells and hepatocytes is thought to occur mainly by 
production of cytokines and inflammatory mediators ([45] Decker, 1998). 
Therefore, high levels of LPS can induce increased NF-κB activation and pronounced 
secretion of TNF-α by Kupffer cells, ultimately leading to endotoxin induced liver injury ([69] 
Hartung, 1997; [167] Su, 2002). In detail, TNF-α release from LPS-treated Kupffer cells 
contributes to hepatocyte necrosis as well as to apoptosis during sepsis ([66] Hamada, 1999; 
[106] Kurose, 1996). Indeed, not only Kupffer cells are supposed to influence hepatocytes 
but also hepatocytes are discussed to mainly enhance LPS-induced effects on Kupffer cells 
by close cell-to-cell interactions ([163] Scott, 2005). Although, we did not use the model of 
co-cultivation, we believe that TNF-α mRNA expression determined in whole liver tissue 
derives mainly from activated Kupffer cells. This assumption is based on two facts. The first 
aspect concerns the NF-κB binding activity. 
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We observed, on the one hand an elevated NF-κB binding activity in LPS treated whole liver 
homogenates and TNF-α stimulated isolated hepatocytes. On the other hand, primary 
isolated hepatocytes have not been responsive to high doses of LPS, implying no effects on 
NF-κB activation and IκBα degradation. The second aspect regarding our investigations on 
isolated hepatocytes do not indicate any changes in TNF-α mRNA expression following 30 
minutes of LPS stimulation (data not shown). Hence, we conclude that only close cell-to-cell 
interactions, between hepatocyte and Kupffer cells, modulate ANP mediated protective 
effects in hepatic inflammation during sepsis. 
Recently published studies indicate, that in hepatocytes the blockage of TNF-α induced  
NF-κB activity causes apoptosis, indicating the existence of cell-dependent NF-κB regulated 
anti-apoptotic genes ([193] Xu, 1998). Moreover, several reports demonstrate that in 
inflammatory conditions NF-κB activation is essential for hepatocyte survival. This activation 
results in the transcription of anti-apoptotic genes, in detail cIAP2 and Bcl-2 ([34] Chu, 1997; 
[198] Zong, 1999). In particular, cIAP2 has been demonstrated to inhibit effector caspase-3 
activity and apoptosis ([158] Schoemaker, 2002). 
As a result of the protective anti-apoptotic function of NF-κB in the liver, only targeting the 
proinflammatory TNF-α induced NF-κB pathway has been excluded. However, tools that 
allow the inhibition of both, the death as well as the NF-κB signaling pathway might still be 
relevant (Figure 4:2). In this context, the usage of the zinc finger protein A20 prevents TNF-α 
induced hepatocyte apoptosis despite its strong inhibitory effect on NF-κB activation ([15] 
Beyaert, 2000; [73] Heyninck, 2003). Therefore, primary reduction of TNF-α expression by 
macrophages accomplished by ANP pretreatment might be a protective tool in the 
inflammatory signaling cascade. 
TNF-α
ANP
Kupffer cell hepatocyte  
Figure 4:2 Hypothesis of the ANP mediated beneficial effects by Kupffer cell and hepatocyte interaction. 
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4.2.2.2 INVOLVEMENT OF PROTEINKINASES 
Akt proteinkinase 
Regarding endotoxemia, various studies have analyzed the role of the PI3K/Akt pathway in 
LPS-induced inflammation. It has been shown that LPS-induced TLR-4 signaling activates 
the PI3K/Akt pathway in human monocytic cells ([54] Fukao, 2003). Additionally, these 
studies indicated that the inhibition of the PI3K/Akt pathway enhanced LPS-induced NF-κB 
activity and consequently increased NF-κB dependent gene expression. Furthermore, 
inhibition of the PI3K pathway strongly increased LPS-induced inflammation and significantly 
reduced the survival time of endotoxemic mice ([157] Schabbauer, 2004; [190] Williams, 
2004). Therefore, the PI3K pathway is supposed to negatively regulate the LPS-induced 
gene expression and plays an important role as a negative feedback regulator that limits 
proinflammatory responses ([65] Guha, 2002). Conclusively, the PI3K/Akt pathway is 
supposed to play a pivotal role in the maintenance of homeostasis and the integrity of the 
immune response during sepsis. 
 In our study, we clearly demonstrate that LPS treatment is accompanied by increased Akt 
phosphorylation in whole liver homogenates as soon as 15 minutes after LPS injection. 
Hence, we presume that our data are in consistence with the hypothesis assuming that the 
PI3K/Akt pathway might be a process that serves as a beneficial mechanism which 
compensates proinflammatory responses. Regarding these protective mechanisms, 
surprisingly, we analyzed reduced proteinkinase Akt phosphorylation in murine liver samples 
derived from ANP pretreated septic mice. This effect might be related to recent findings in 
reduction of LPS-induced NF-κB activation in ANP pretreated liver samples. For this reason, 
besides LPS signaling pathways, we might also have to focus on TNF-α mediated 
inflammatory responses in the liver. As previously discussed, hepatocytes are mainly 
resistant to apoptosis following TNF-α stimulation ([186] Wang, 1995). This effect is 
explained by the fact that the TNF-α-TNFR-1 pathway not only triggers downstream signals 
leading to apoptosis but also induces an NF-κB dependent anti-apoptotic signaling cascade 
([158] Schoemaker, 2002). Additionally, several studies focused on the role of the PI3K/Akt 
pathway within this protective anti-apoptotic mechanism. These studies indicate that not only 
the inducible activation of NF-κB but also the constitutively activation of Akt signaling 
regulated hepatocyte survival against TNF-α stimulation ([79] Imose, 2003). Moreover, it has 
been cited, that Akt activation protects murine hepatocytes from TNF-α mediated apoptosis 
through NF-κB activation. These findings primarily link the TNF-α-induced NF-κB mediated 
anti-apoptotic signaling cascade to Akt activation in hepatocytes ([70] Hatano, 2001). 
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Whether Akt mediated NF-κB activation is caused by enhanced IκBα phosphorylation is still 
discussed ([122] Madrid, 2000; [145] Ozes, 1999). Indeed, most studies have not found any 
evidence for the involvement of Akt activation in IκBα degradation. These studies rather 
propose a mechanism independent of IκBα. In this pathway activation of Akt affects the 
transcriptional activity of NF-κB by phosphorylating the NF-κB subunit p65 ([122] Madrid, 
2000). 
However, besides this controversy, we can conclude that on the one hand determined Akt 
activation is initiated by direct responding to LPS administration. On the other hand, 
increased phosphorylation might also be a result of preceding TNF-α expression. 
Constitutively, regarding the latter, the reduction in Akt phosphorylation determined in our 
studies could consequentially be connected to impaired TNF-α expression in ANP pretreated 
endotoxemic liver samples. 
p38 MAPK 
As mentioned in chapter 1.3.2.4 the p38 MAPK has firstly been described in LPS stimulated 
murine macrophages ([67] Han, 1994). Hereon, the p38 MAPK was shown to be critically 
involved in LPS-induced TNF-α gene and consecutive protein expression ([31] Carter, 
1999b; [111] Lee, 1994). Interestingly, in human macrophages, the inhibition of LPS-induced 
p38 MAPK activation decreases NF-κB activation as well as TNF-α gene expression. 
Consequently, p38 MAPK mediated gene expression is supposed to require NF-κB 
activation ([30] Carter, 1999a). Furthermore, LPS-induced p38 MAPK activation in murine 
macrophages is widely discussed to influence TNF-α mRNA stability. Thus, stimulation of a 
murine macrophage cell line with endotoxin resulted in stabilization of TNF-α mRNA, which 
has been reversed by specific inhibition of p38 MAPK. 
As our studies clearly indicate, p38 MAPK phosphorylation is highly decreased in whole liver 
homogenates derived from LPS treated mice, pointing to reduced p38 MAPK activation. Most 
investigations exclusively focus on activated macrophages. Therefore, regarding the entire 
organ, our effect might be beneficial by limiting p38 MAPK activation, following TNF-α 
expression in inflammatory and septic disorders. Unexpectedly, ANP preconditioning does 
not have any influence on p38 MAPK activation compared to solely LPS treated liver 
samples. Conclusively, we can say that reduction of p38 MAPK activation is supposedly an 
important parameter in inflammatory processes, whereas ANP preconditioning does not 
mediate its protective effects by influencing the signaling cascades leading to changes in p38 
MAPK activation. 
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4.3 BLOOD DERIVED LEUKOCYTES 
As mentioned above, the induction of TNF-α expression in macrophages represents an 
important pathomechanism in various inflammatory processes. Therefore, based on our 
effects determined in murine liver tissue, we are especially interested in the ANP mediated 
regulatory mechanism of LPS-induced TNF-α production. In order to corroborate the 
hypothesis of the special relevance of macrophages in ANP mediated beneficial effects, we 
focused on blood derived leukocytes. In our laboratory, recent findings indicate the major 
impact of macrophages on reduction of LPS-induced TNF-α expression. ANP was shown to 
attenuate TNF-α production in LPS-activated murine bone marrow derived macrophages via 
a cGMP dependent mechanism at the transcriptional level ([95] Kiemer, 2000). This 
synthesis is mainly regulated via the proinflammatory transcription factor NF-κB ([182] 
Vollmar, 2005). Additionally, in resident liver macrophages, also denoted as Kupffer cells, 
ANP has also been demonstrated to specifically interact with TNF-α cytokine expression. 
Interestingly, regulatory mechanisms determined in Kupffer cells clearly differ from those 
preliminary determined in murine bone marrow macrophages. LPS-induced TNF-α mRNA 
expression was not significantly affected by ANP treatment. Therefore, an influence of ANP 
on posttranscriptional processing of LPS-induced TNF-α production has primarily been 
suggested. Moreover, ANP was shown to markedly increase cell associated TNF-α in LPS 
stimulated Kupffer cells ([94] Kiemer, 2002a). TNF-α is initially synthesized as a membrane 
bound, cell associated protein (memTNF-α) that is further cleaved to yield the soluble form 
(see chapter 1.3.2.2). Above mentioned, these two forms of TNF-α have apparently different 
activities. In regard to LPS-mediated liver injury, secreted TNF-α, also referred to as soluble 
TNF-α (solTNF-α), was shown to mainly mediate mechanisms finally leading to hepatic 
dysfunction ([142] Nowak, 2000). Therefore, a therapeutic agent which primarily inhibits the 
expression or the release of TNF-α from the cell surface might preserve the benefits of these 
cytokines, by preventing TNF-α induced damage. In former experiments, including blood 
derived leukocytes from human donors, it has been demonstrated that ANP significantly 
inhibited the production of TNF-α in LPS stimulated blood samples ([95] Kiemer, 2000). On 
the base of these findings, we primarily aimed to investigate changes in TNF-α protein 
expression in murine leukocytes. Our studies demonstrate, that total LPS-induced TNF-α 
protein concentrations determined in murine leukocytes seem to be slightly decreased in 
ANP pretreated murine leukocytes. Additionally, determination of cell membrane associated 
TNF-α protein contents revealed this slight reduction. 
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Conclusively, we can ascertain that reduced total TNF-α protein levels determined in murine 
leukocytes are likely to be reflected in cell surface TNF-α protein contents. 
As commonly accepted, cytokines are not accumulated intracellularly and their secretion 
mainly depends on new protein synthesis. However, it should be noted, that neutrophils that 
comprise approximately 80% of all leukocytes, contain very low levels of total messenger 
RNA compared to mononuclear cells ([93] Kermarrec, 2005). Therefore, mRNA isolation for 
accurate analysis of changes in TNF-α gene expression by real time RT-PCR would have 
required to large murine blood volumes. Consequently, we aimed to investigate the influence 
of ANP on LPS-induced TNF-α mRNA expression in human blood leukocytes. As previously 
determined in whole liver-tissue, we supposed reduced TNF-α mRNA expression in ANP 
pretreated LPS stimulated white blood cells. Unexpectedly, as our studies clearly 
demonstrate, we have not been able to determine any changes in TNF-α mRNA expression 
in ANP pretreated human leukocytes compared to solely LPS stimulated cells. Interestingly, 
recent studies demonstrated that linking the murine and human LPS-models into one 
definitive comparison, such as TNF-α expression proves to be very difficult. However, 
although differences exist, there are several similarities in the inflammatory response to 
endotoxin in mice and humans. In detail, humans clearly demonstrated a physiological 
response which has not been evident in mice. However, the cytokine induction patterns in 
mice and humans were similar, although greater concentrations of endotoxin were needed to 
induce the same response in mice ([38] Copeland, 2005; [132] Mestas, 2004). Consequently, 
we analyzed the same parameter as preliminary determined in murine blood samples, in 
particular TNF-α cell surface expression by utilizing varying LPS and ANP concentrations. In 
our studies, we examined the expression of memTNF-α in stimulated neutrophils and 
monocytes. Cell associated TNF-α has clearly been detectable on the cell surface of resting 
neutrophils as well as on monocytes. Interestingly, upon stimulation with low dose of 
endotoxin, TNF-α accumulated on the cell surface, indicating primarily elevated transport of 
TNF-α protein to the cell surface. In contrast, high LPS concentrations subsequently resulted 
in decreased memTNF-α levels in both investigated cell types, pointing to immediately 
increased TNF-α cleavage from the cell surface. Supporting these effects, the very identical 
phenomenon has recently been described for LPS treated human blood monocytes by 
Robertshaw and colleagues ([155] Robertshaw, 2005). As mentioned above, in Kupffer cells, 
ANP has primarily been suggested to interfere in posttranscriptional TNF-α protein 
processing, resulting in enhanced cell-associated TNF-α contents ([94] Kiemer, 2002a). 
Regarding the latter, there are two assumed ways of interference, either inhibiting the 
transport to, or preventing the cleavage of TNF-α from the cell membrane. 
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Both effects finally cause accumulated cell associated TNF-α amounts. Interestingly, the 
theoretical consequence of blocking the TNF-α cleavage would be the accumulation of 
membrane bound TNF-α on the cell surface ([56] Gearing, 1995). As previously determined 
in murine blood samples, ANP preconditioning in LPS treated human blood leukocytes did 
not yield enhanced TNF-α cell surface expression, but rather minimized detectable 
memTNF-α protein amounts compared to low dose LPS stimulated cells in a dose 
dependent manner. Interestingly, following inhibition of TNF-α processing, previous studies 
focusing on TNF-α in peripheral blood mononuclear cells showed an accumulation of 
proTNF-α in the golgi-apparatus rather than on the cell surface ([128] McGeehan, 1994). 
These findings might be in consistence with determined cell associated TNF-α levels in 
murine Kupffer cells, as membrane bound TNF-α has not been itemized ([94] Kiemer, 
2002a). This might also be a possible mechanism responsible for the outcome of our 
experiments. These complex details will certainly be very interesting to be analyzed in the 
future. Moreover, high dose LPS concentrations employed for experiments with murine blood 
samples entirely removed memTNF-α from the cell surface, whereas any ANP mediated 
beneficial effect has completely been abolished. Finally, these findings might elucidate 
preliminary unexplainable determined TNF-α mRNA expression in human blood leukocytes. 
Therefore, we are not able to clearly exclude ANP interference in TNF-α gene expression up 
to this point. Based on these primary investigations of ANP interference in blood leukocytes, 
further investigations have to be accomplished. These studies will focus on whether ANP 
mediated effects on LPS-induced TNF-α expression are rather caused on the transcriptional 
or the posttranscriptional level. 
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4.4 SUMMARY 
Altogether, as shown in Figure 4:3, we have proven that ANP mediated effects are diverse 
yet similar in different organs derived from endotoxemic mice and in isolated blood 
leukocytes. These ANP mediated interactions are proceeding at the onset of LPS-induced 
inflammation and sepsis. 
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Figure 4:3 Determined ANP mediated protective effects in early inflammatory pathways. 
Primarily, we can clearly demonstrate that ANP preconditioning in endotoxemic mice yields  
TNF-α m-RNA reduction, determined in the spleen as well as in the liver. 
As investigated in whole liver tissue, ANP preconditioning mediates its beneficial effects by 
reducing LPS-induced transcription factor NF-κB activation. This reduction is caused by 
decreased phosphorylation of the NF-κB inhibitory factor IκBα, proximately leading to 
impaired degradation of IκBα protein. Thus, enhanced IκBα protein level in the cytosol 
prevent NF-κB translocation into the nucleus, and subsequently transcription factor activity 
and gene expression. These effects might be caused by or lead to the reduction in TNF-α 
gene expression, finally preventing liver failure. 
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Secondly, besides the transcriptional regulation of TNF-α gene expression determined in 
spleen and liver tissue, we focused on ANP mediated effects in LPS stimulated murine and 
human blood derived leukocytes. Following LPS stimulation, we observed reduced total  
TNF-α protein levels as well as decreased TNF-α amounts on the cell-surface in ANP 
preconditioned blood leukocytes, respectively monocytes and neutrophils. These initial 
investigations indicate that the reduced TNF-α protein levels in leukocytes might either be 
evoked by interference of ANP in transcriptional or posttranscriptional processes. 
Eventually, due to its effects on key events of cell activation, such as the reduction of  
LPS-induced TNF-α expression, ANP may represent a promising beneficial autocrine 
substance in modulating early inflammatory signaling pathways. 
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5.1 mRNA SEQUENCES FOR REAL TIME RT-PCR ANALYSIS 
DEFINITION:   tumour necrosis factor-α (TNF-α) mRNA 
ACCESSION:  M10988 
SOURCE:       Homo sapiens (human) 
ORIGIN  1 cacaccctga caagctgcca ggcaggttct cttcctctca catactgacc cacggctcca 
       61 ccctctctcc cctggaaagg acaccatgag cactgaaagc atgatccggg acgtggagct 
      121 ggccgaggag gcgctcccca agaagacagg ggggccccag ggctccaggc ggtgcttgtt 
      181 cctcagcctc ttctccttcc tgatcgtggc aggcgccacc acgctcttct gcctgctgca 
      241 ctttggagtg atcggccccc agagggaaga gtcccccagg gacctctctc taatcagccc 
      301 tctggcccag gcagtcagat catcttctcg aaccccgagt gacaagcctg tagcccatgt 
      361 tgtagcaaac cctcaagctg aggggcagct ccagtggctg aaccgccggg ccaatgccct 
      421 cctggccaat ggcgtggagc tgagagataa ccagctggtg gtgccatcag agggcctgta 
      481 cctcatctac tcccaggtcc tcttcaaggg ccaaggctgc ccctccaccc atgtgctcct 
      541 cacccacacc atcagccgca tcgccgtctc ctaccagacc aaggtcaacc tcctctctgc 
      601 catcaagagc ccctgccaga gggagacccc agagggggct gaggccaagc cctggtatga 
      661 gcccatctat ctgggagggg tcttccagct ggagaagggt gaccgactca gcgctgagat 
      721 caatcggccc gactatctcg actttgccga gtctgggcag gtctactttg ggatcattgc 
      781 cctgtgagga ggacgaacat ccaaccttcc caaacgcctc ccctgcccca atccctttat 
      841 taccccctcc ttcagacacc ctcaacctct tctggctcaa aaagagaatt gggggcttag 
      901 ggtcggaacc caagcttaga actttaagca acaagaccac cacttcgaaa cctgggattc 
      961 aggaatgtgt ggcctgcaca gtgaagtgct ggcaaccact aagaattcaa actggggcct 
     1021 ccagaactca ctggggccta cagctttgat ccctgacatc tggaatctgg agaccaggga 
     1081 gcctttggtt ctggccagaa tgctgcagga cttgagaaga cctcacctag aaattgacac 
     1141 aagtggacct taggccttcc tctctccaga tgtttccaga cttccttgag acacggagcc 
     1201 cagccctccc catggagcca gctccctcta tttatgtttg cacttgtgat tatttattat 
     1261 ttatttatta tttatttatt tacagatgaa tgtatttatt tgggagaccg gggtatcctg 
     1321 ggggacccaa tgtaggagct gccttggctc agacatgttt tccgtgaaaa cggaggctga 
     1381 acaataggct gttcccatgt agccccctgg cctctgtgcc ttcttttgat tatgtttttt 
     1441 aaaatattat ctgattaagt tgtctaaaca atgctgattt ggtgaccaac tgtcactcat 
     1501 tgctgaggcc tctgctcccc agggagttgt gtctgtaatc ggcctactat tcagtggcga 
     1561 gaaataaagg ttgcttagga aagaa  // 
 
 
DEFINITION: glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA 
ACCESSION: NM_002046 
SOURCE:      Homo sapiens (human) 
ORIGIN  1 aaattgagcc cgcagcctcc cgcttcgctc tctgctcctc ctgttcgaca gtcagccgca 
       61 tcttcttttg cgtcgccagc cgagccacat cgctcagaca ccatggggaa ggtgaaggtc 
      121 ggagtcaacg gatttggtcg tattgggcgc ctggtcacca gggctgcttt taactctggt 
      181 aaagtggata ttgttgccat caatgacccc ttcattgacc tcaactacat ggtttacatg 
      241 ttccaatatg attccaccca tggcaaattc catggcaccg tcaaggctga gaacgggaag 
      301 cttgtcatca atggaaatcc catcaccatc ttccaggagc gagatccctc caaaatcaag 
      361 tggggcgatg ctggcgctga gtacgtcgtg gagtccactg gcgtcttcac caccatggag 
      421 aaggctgggg ctcatttgca ggggggagcc aaaagggtca tcatctctgc cccctctgct 
      481 gatgccccca tgttcgtcat gggtgtgaac catgagaagt atgacaacag cctcaagatc 
      541 atcagcaatg cctcctgcac caccaactgc ttagcacccc tggccaaggt catccatgac 
      601 aactttggta tcgtggaagg actcatgacc acagtccatg ccatcactgc cacccagaag 
      661 actgtggatg gcccctccgg gaaactgtgg cgtgatggcc gcggggctct ccagaacatc 
      721 atccctgcct ctactggcgc tgccaaggct gtgggcaagg tcatccctga gctgaacggg 
      781 aagctcactg gcatggcctt ccgtgtcccc actgccaacg tgtcagtggt ggacctgacc 
      841 tgccgtctag aaaaacctgc caaatatgat gacatcaaga aggtggtgaa gcaggcgtcg 
      901 gagggccccc tcaagggcat cctgggctac actgagcacc aggtggtctc ctctgacttc 
      961 aacagcgaca cccactcctc cacctttgac gctggggctg gcattgccct caacgaccac 
     1021 tttgtcaagc tcatttcctg gtatgacaac gaatttggct acagcaacag ggtggtggac 
     1081 ctcatggccc acatggcctc caaggagtaa gacccctgga ccaccagccc cagcaagagc 
     1141 acaagaggaa gagagagacc ctcactgctg gggagtccct gccacactca gtcccccacc 
     1201 acactgaatc tcccctcctc acagttgcca tgtagacccc ttgaagaggg gaggggccta 
     1261 gggagccgca ccttgtcatg taccatcaat aaagtaccct gtgctcaacc  // 
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DEFINITION:   tumour necrosis factor-α (TNF-α) mRNA 
ACCESSION:   NM_013693 
SOURCE:  Mus musculus (house mouse) 
ORIGIN  1 cctcagcgag gacagcaagg gactagccag gagggagaac agaaactcca gaacatcttg 
       61 gaaatagctc ccagaaaagc aagcagccaa ccaggcaggt tctgtccctt tcactcactg 
      121 gcccaaggcg ccacatctcc ctccagaaaa gacaccatga gcacagaaag catgatccgc 
      181 gacgtggaac tggcagaaga ggcactcccc caaaagatgg ggggcttcca gaactccagg 
      241 cggtgcctat gtctcagcct cttctcattc ctgcttgtgg caggggccac cacgctcttc 
      301 tgtctactga acttcggggt gatcggtccc caaagggatg agaagttccc aaatggcctc 
      361 cctctcatca gttctatggc ccagaccctc acactcagat catcttctca aaattcgagt 
      421 gacaagcctg tagcccacgt cgtagcaaac caccaagtgg aggagcagct ggagtggctg 
      481 agccagcgcg ccaacgccct cctggccaac ggcatggatc tcaaagacaa ccaactagtg 
      541 gtgccagccg atgggttgta ccttgtctac tcccaggttc tcttcaaggg acaaggctgc 
      601 cccgactacg tgctcctcac ccacaccgtc agccgatttg ctatctcata ccaggagaaa 
      661 gtcaacctcc tctctgccgt caagagcccc tgccccaagg acacccctga gggggctgag 
      721 ctcaaaccct ggtatgagcc catatacctg ggaggagtct tccagctgga gaagggggac 
      781 caactcagcg ctgaggtcaa tctgcccaag tacttagact ttgcggagtc cgggcaggtc 
      841 tactttggag tcattgctct gtgaagggaa tgggtgttca tccattctct acccagcccc 
      901 cactctgacc cctttactct gaccccttta ttgtctactc ctcagagccc ccagtctgtg 
      961 tccttctaac ttagaaaggg gattatggct cagagtccaa ctctgtgctc agagctttca 
     1021 acaactactc agaaacacaa gatgctggga cagtgacctg gactgtgggc ctctcatgca 
     1081 ccaccatcaa ggactcaaat gggctttccg aattcactgg agcctcgaat gtccattcct 
     1141 gagttctgca aagggagagt ggtcaggttg cctctgtctc agaatgaggc tggataagat 
     1201 ctcaggcctt cctaccttca gacctttcca gactcttccc tgaggtgcaa tgcacagcct 
     1261 tcctcacaga gccagccccc ctctatttat atttgcactt attatttatt atttatttat 
     1321 tatttattta tttgcttatg aatgtattta tttggaaggc cggggtgtcc tggaggaccc 
     1381 agtgtgggaa gctgtcttca gacagacatg ttttctgtga aaacggagct gagctgtccc 
     1441 cacctggcct ctctaccttg ttgcctcctc ttttgcttat gtttaaaaca aaatatttat 
     1501 ctaacccaat tgtcttaata acgctgattt ggtgaccagg ctgtcgctac atcactgaac 
     1561 ctctgctccc cacgggagcc gtgactgtaa ttgccctaca gtcaattgag agaaataaa 
// 
 
 
DEFINITION: hypoxanthine guanine phosphoribosyl transferase(HPRT-1) mRNA 
ACCESSION:    NM_013556 
SOURCE:  Mus musculus (house mouse) 
ORIGIN  1 ttacctcact gctttccgga gcggtagcac ctcctccgcc ggcttcctcc tcagaccgct 
       61 ttttgccgcg agccgaccgg tcccgtcatg ccgacccgca gtcccagcgt cgtgattagc 
      121 gatgatgaac caggttatga cctagatttg ttttgtatac ctaatcatta tgccgaggat 
      181 ttggaaaaag tgtttattcc tcatggactg attatggaca ggactgaaag acttgctcga 
      241 gatgtcatga aggagatggg aggccatcac attgtggccc tctgtgtgct caaggggggc 
      301 tataagttct ttgctgacct gctggattac attaaagcac tgaatagaaa tagtgataga 
      361 tccattccta tgactgtaga ttttatcaga ctgaagagct actgtaatga tcagtcaacg 
      421 ggggacataa aagttattgg tggagatgat ctctcaactt taactggaaa gaatgtcttg 
      481 attgttgaag atataattga cactggtaaa acaatgcaaa ctttgctttc cctggttaag 
      541 cagtacagcc ccaaaatggt taaggttgca agcttgctgg tgaaaaggac ctctcgaagt 
      601 gttggataca ggccagactt tgttggattt gaaattccag acaagtttgt tgttggatat 
      661 gcccttgact ataatgagta cttcaggaat ttgaatcacg tttgtgtcat tagtgaaact 
      721 ggaaaagcca aatacaaagc ctaagatgag cgcaagttga atctgcaaat acgaggagtc 
      781 ctgttgatgt tgccagtaaa attagcaggt gttctagtcc tgtggccatc tgcctagtaa 
      841 agctttttgc atgaaccttc tatgaatgtt actgttttat ttttagaaat gtcagttgct 
      901 gcgtccccag acttttgatt tgcactatga gcctataggc cagcctaccc tctggtagat 
      961 tgtcgcttat cttgtaagaa aaacaaatct cttaaattac cacttttaaa taataatact 
     1021 gagattgtat ctgtaagaag gatttaaaga gaagctatat tagtttttta attggtattt 
     1081 taatttttat atattcagga gagaaagatg tgattgatat tgttaattta gacgagtctg 
     1141 aagctctcga tttcctatca gtaacagcat ctaagaggtt ttgctcagtg gaataaacat 
     1201 gtttcagcag tgttggctgt attttcccac tttcagtaaa tcgttgtcaa cagttccttt 
     1261 taaatgcaaa taaataaatt ctaaaaatt  // 
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5.2 ABREVIATIONS 
Akt Proteinkinase B 
ANP Atrial natriuretic peptide 
AP1 Activator protein-1 
APC Activated protein C 
APS Ammonium persulfate 
AT Anti-thrombin 
BNP Brain natriuretic peptide 
BSA Bovine serum albumin 
CAPS Cyclohexylamino-1-propane sulfonic acid 
cDNA Complementary DNA 
cGMP Cyclic-guanosise-monophosphate 
CHAPS 3-[(3-Cholamidopropyldimethylammanio]-1-propanesulfonate 
CNP C-type natriuretic peptide 
COX2 Cyclo-oxygenase 2 
DNA Desoxyribonucleic acid 
DNP Dendroaspis natriuretic peptide 
DTT Dithiothreitol 
ECL Enhanced Chemoluminescence 
EDTA Ethylendiamintetraacetic acid 
EGTA Ethylene-glycol-bis(2-aminoethylether)tetraacetic acid 
ELISA Enzyme linked immuno sorbent assay 
EMSA Electro mobility shift assay 
Erk Extracellular-signal-regulated kinase 
FACS Fluorescence activated cell sorter 
FADD FAS-associated death domain protein 
FCS Foetal calf serum 
FL-1 Fluorescence channel 1 
FSC Forward scatter 
GCase Guanylate-cyclase 
h hour 
HBSS Hank’s balanced salt solution 
HEPES N-(2-Hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid) 
IκBα/β/ε Inhibitory factor-κBα/β/ε 
IKK IκB-kinase complex 
IL-1 Interleukin-1 
iNOS Inducible NO-synthase 
IRAK IL-1 receptor associated kinase 
JNK c-Jun amino-terminal kinases 
KC Kupffer cells 
LBP LPS-binding protein 
LPS Lipopolysaccharide 
LRR Leucine rich repeats 
LTA Lipoteichoic acid 
MAPK Mitogen-activated protein kinase 
MAPKK Mitogen-activated protein kinase kinase 
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MAPKKK Mitogen-activated protein kinase kinase kinase 
memTNF-α Membrane bound tumor necrosis factor-α 
MKK3/6 Mitogen-activated protein kinase kinase 3/6 
mRNA Messenger ribonucleic acid 
MyD88 Myeloid differentiation factor-88  
NEMO Nuclear factor-κB essential modulator 
NF-κB Nuclear factor-κB 
NO Nitric oxide 
NP Natriuretic peptide 
NPR-A Natriuretic peptide receptor-A / A-type natriuretic receptor 
NPR-B Natriuretic peptide receptor-B / B-type natriuretic receptor 
NPR-C Natriuretic peptide receptor-C / C-type natriuretic receptor 
PAA Polyacrylamide 
PAI Plasminogen-activator inhibitor 
PAMP Pathogen-associated molecular pattern 
PBMC Peripheral blood mononuclear cells 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PGE2 Prostaglandine-E2
PI3K Phosphatidylinositol 3 kinase 
PMSF Phenylmethanesulfonylfluoride 
PVDF Polyvinylidene fluoride 
RAAS Renin-angiotensin-aldosteron system 
RIP Receptor interacting protein 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
SDS Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM Standard error of the mean value 
solTNF-α Soluble tumor necrosis factor-α 
STE Sodium chloride, Tris, EDTA buffer 
TACE TNF-α cleaving enzyme 
TBE Tris, borate, EDTA buffer 
TBS-T Tris buffered saline with Tween-20 
TE Tris-EDTA buffer 
TEMED N, N, N’, N’ tetramethylethylene diamine 
TF Tissue factor 
TFPI Tissue factor pathway inhibitor 
TIR Toll/IL-1 receptor homology domain 
TLR Toll-like receptors 
TNF-α Tumor necrosis factor-α 
TNFR-1/2 Tumor necrosis factor receptor-1/2 
TNP Taipan venom natriuretic peptide 
TRADD Tumor necrosis factor receptor-1 associated death domain 
TRAF2 Tumor necrosis factor receptor associated factor 2 
TRAF6 Tumor necrosis factor receptor associated factor 6 
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5.3 ALPHABETICAL ORDER OF COMPANIES 
 
Agfa-Gevaert AG Munich Germany 
Alexis Biochemicals Grünberg Germany 
Amersham Pharmacia Biotech Uppsala Sweden 
Aventis Frankfurt Germany 
B. Braun Melsungen Melsungen Germany 
Bachem Heidelberg Germany 
BD Biosciences Heidelberg Germany 
BD Labware Bedford USA 
Beckmann Instruments Munich Germany 
Bioclot Aidenbach  Germany 
Biomers Ulm Germany 
Biometra Göttingen Germany 
Biorad Laboratories Munich Germany 
Biozol GmbH Eching Germany 
Calbiochem Novabiochem Schwalbach Germany 
Canberra-Packard GmbH Dreieich Germany 
Cell Signaling Frankfurt/Main Germany 
Charles River WIGA GmbH Sulzfeld Germany 
Dako Cytomation GmbH Glostrup Denmark 
Dianova Hamburg Germany 
Endogen Rockford USA 
Finnzymes/New England Biolabs Espoo Finnland 
Fuji Photo Film GmbH Düsseldorf Germany 
Gibco Invitrogen Corporation Karlsruhe Germany 
GraphPad Software Inc. San Diego USA 
Kodak  Rochester USA 
Millipore Bedford USA 
Molecular Probes/Invitrogen/Caltag Karlsruhe Germany 
NEN Life Science Products Cologne Germany 
Owl separation Systems Porthsmouth USA 
Pan Biotech GmbH Aidenbach Germany 
PromoCell Heidelberg Germany 
Qiagen GmbH Hilden Germany 
Roche Diagnostics GmbH Mannheim Germany 
Sanofi-Ceva Düsseldorf Germany 
Santa Cruz Biotechnology Heidelberg Germany 
Serva Heidelberg Germany 
Sigma-Aldrich Taufkirchen Germany 
Sniff GmbH Soest Germany 
Ssniff Soest Germany 
Stratagene Heidelberg Germany 
Thermo Shandon GmbH Frankfurt Germany 
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